<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004427.pub4" GROUP_ID="NEUROMUSC" ID="421203070716445559" MERGED_FROM="" MODIFIED="2017-10-02 17:53:46 +0100" MODIFIED_BY="Sophie Maprayil" REVIEW_NO="072" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-10-02 17:53:42 +0100" MODIFIED_BY="Sophie Maprayil">
<TITLE MODIFIED="2017-08-07 10:10:45 +0100" MODIFIED_BY="Ruth Brassington">Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease</TITLE>
<CONTACT MODIFIED="2017-10-02 17:53:42 +0100" MODIFIED_BY="Sophie Maprayil"><PERSON ID="D7E4838282E26AA20046B372E4A71284" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aleksandar</FIRST_NAME><LAST_NAME>Radunovic</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>Aleksandar.Radunovic@bartshealth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Barts MND Centre</DEPARTMENT><ORGANISATION>Royal London Hospital</ORGANISATION><ADDRESS_1>Whitechapel</ADDRESS_1><CITY>London</CITY><ZIP>E1 1BB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+442035941194</PHONE_1><FAX_1>+442035942153</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-10-02 17:53:42 +0100" MODIFIED_BY="Sophie Maprayil"><PERSON ID="D7E4838282E26AA20046B372E4A71284" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aleksandar</FIRST_NAME><LAST_NAME>Radunovic</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>Aleksandar.Radunovic@bartshealth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Barts MND Centre</DEPARTMENT><ORGANISATION>Royal London Hospital</ORGANISATION><ADDRESS_1>Whitechapel</ADDRESS_1><CITY>London</CITY><ZIP>E1 1BB</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+442035941194</PHONE_1><FAX_1>+442035942153</FAX_1></ADDRESS></PERSON><PERSON ID="5686" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Djillali</FIRST_NAME><LAST_NAME>Annane</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>djillali.annane@aphp.fr</EMAIL_1><ADDRESS><DEPARTMENT>Critical Care Department</DEPARTMENT><ORGANISATION>Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris, and Université Versailles &#8211; Pari Saclay</ORGANISATION><ADDRESS_1>104. Boulevard Raymond Poincaré</ADDRESS_1><CITY>Garches</CITY><ZIP>92380</ZIP><REGION>Ile de France</REGION><COUNTRY CODE="FR">France</COUNTRY><PHONE_1>+33 1 47 10 77 86</PHONE_1><PHONE_2>+33 1 47 10 77 87</PHONE_2><FAX_1>+33 1 47 10 77 83</FAX_1></ADDRESS></PERSON><PERSON ID="20329583022738294649120330113631" ROLE="AUTHOR"><FIRST_NAME>Muhammad</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Rafiq</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>m.k.rafiq@sheffield.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Neurology Unit</DEPARTMENT><ORGANISATION>University of Sheffield</ORGANISATION><CITY>Sheffield</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="9D90184382E26AA200C3FEB648B5FC66" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><LAST_NAME>Brassington</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>cochranenmd@ion.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)203 448 8134</PHONE_1><FAX_1>+44 (0)203 448 4725</FAX_1></ADDRESS></PERSON><PERSON ID="15419" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Naveed</FIRST_NAME><LAST_NAME>Mustfa</LAST_NAME><EMAIL_1>naveed.mustfa@uhns.nhs.uk</EMAIL_1><EMAIL_2>naveed@doctors.org.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Respiratory Medicine</DEPARTMENT><ORGANISATION>Royal Stoke University Hospital, University Hospital of North Midlands</ORGANISATION><ADDRESS_1>Newcastle Road</ADDRESS_1><CITY>Stoke-on-Trent</CITY><ZIP>ST4 6QG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-01-31 19:31:24 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="30" MONTH="1" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="1" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="1" YEAR="2021"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-09-14 14:04:11 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-08-31 14:28:03 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="30" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>Searches were updated to January 2017.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-09-14 14:04:11 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="30" MONTH="1" YEAR="2017"/>
<DESCRIPTION>
<P>New searches performed. We identified no new included studies. We updated some of the methodology and added a 'Summary of findings' table. We searched trials registries for ongoing or completed but unreported trials. We determined the status of apparently unpublished registered trials via contact with trial authors.</P>
<P>We added quality of life data from <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>, for completeness of reporting.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-08-31 14:28:45 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-08-31 14:28:45 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="24" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Searches updated to May 2012, no new trials included. We updated the Background and edited the review. Muhammad K Rafiq and Ruth Brassington are new authors. Kate Jewitt has withdrawn.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-28 14:15:07 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="6" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>This is an update of a review first published in 2009.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-10 10:23:04 +0000" MODIFIED_BY="Kate Jewitt">
<DATE DAY="23" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-02-02 12:15:25 +0000" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2017-02-02 12:15:25 +0000" MODIFIED_BY="Ruth Brassington">
<SOURCE>
<NAME>Institute of Psychiatry</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Guy's, King's &amp; St. Thomas' School of Medicine, King's College London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Hopital Raymond Poincaré, Garches</NAME>
<COUNTRY CODE="FR">France</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-02-02 12:15:25 +0000" MODIFIED_BY="Ruth Brassington">
<NAME>National Institute of Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-01-28 12:13:00 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Motor Neurone Disease Association</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-01-28 12:13:00 +0000" MODIFIED_BY="[Empty name]">
<NAME>Muscular Dystrophy Association</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-10-02 17:52:10 +0100" MODIFIED_BY="Sophie Maprayil">
<SUMMARY MODIFIED="2017-09-18 14:49:35 +0100" MODIFIED_BY="Sophie Maprayil">
<TITLE MODIFIED="2017-08-31 14:32:02 +0100" MODIFIED_BY="Ruth Brassington">Mechanical ventilation for people with amyotrophic lateral sclerosis/motor neuron disease</TITLE>
<SUMMARY_BODY MODIFIED="2017-09-18 14:49:35 +0100" MODIFIED_BY="Sophie Maprayil">
<P>
<B>Review question</B>
</P>
<P>Does mechanical ventilation improve the survival of people with amyotrophic lateral sclerosis (ALS)? How does it affect disease progression and quality of life, and does it have any unwanted effects?</P>
<P>
<B>Background</B>
</P>
<P>Amyotrophic lateral sclerosis, also known as motor neuron disease, is a condition in which nerves that control movement are lost. Management of ALS has evolved rapidly in the last 10 years. Although there is still no cure, some treatments can help manage symptoms. Amyotrophic lateral sclerosis causes progressive muscle weakness, including weakness of the muscles used in breathing. Failure of ventilation (the capacity to move air in and out of the lungs) is an important cause of death in ALS. Mechanical ventilation is a method in which machines support the person's breathing. Mechanical ventilation may be invasive or non-invasive. Invasive ventilation involves insertion of a tube into the throat (tracheostomy). Non-invasive ventilation (NIV) is a method of helping people breathe that does not require a tracheostomy. Non-invasive ventilation supports breathing via a mask on the face or nose that is connected via tubing to a small portable ventilator.</P>
<P>
<B>Study characteristics</B>
</P>
<P>In this updated review, we examined the evidence from two randomised trials of NIV in ALS involving a total of 54 participants. One of the trials, which studied when to start NIV, provided no usable data. A third trial, identified in a clinical trials register, currently has no published results.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>Complete data were only available from a single trial of 41 participants. The results of this trial provided moderate-quality evidence that NIV significantly prolongs survival, and low-quality evidence that it improves or maintains quality of life compared to standard care. Median survival was increased by an estimated 48 days, from 171 to 219 days. The survival benefit from NIV was much greater in people with ALS in whom the muscles used for speaking, chewing, and swallowing (bulbar muscles) were either unaffected or only moderately weak. Among these 20 participants, the median survival with NIV was increased by an estimated 205 days (216 days with NIV, compared to 11 days with standard care). Quality of life was also maintained in participants with mild to moderate bulbar weakness. In the 21 participants with severe bulbar weakness, NIV did not prolong survival or maintain quality of life scores, although a sleep-related symptoms score improved. Neither trial reported on adverse effects. Participants and clinicians were aware of the treatment groups, which can influence quality of life assessments.</P>
<P>More trials of NIV versus standard care in ALS are unlikely as it would not be ethical to withhold NIV. Future studies should examine early intervention with NIV and determine the best time to start it.</P>
<P>The evidence is up to date to January 2017.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-08-31 14:56:34 +0100" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2017-08-31 14:28:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is a fatal neurodegenerative disease. Neuromuscular respiratory failure is the most common cause of death, which usually occurs within two to five years of the disease onset. Supporting respiratory function with mechanical ventilation may improve survival and quality of life. This is the second update of a review first published in 2009.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-06 13:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of mechanical ventilation (tracheostomy-assisted ventilation and non-invasive ventilation (NIV)) on survival, functional measures of disease progression, and quality of life in ALS, and to evaluate adverse events related to the intervention.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-08-31 14:29:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL Plus, and AMED on 30 January 2017. We also searched two clinical trials registries for ongoing studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-05-18 16:57:55 +0100" MODIFIED_BY="Ruth  Brassington">
<P>Randomised controlled trials (RCTs) and quasi-RCTs involving non-invasive or tracheostomy-assisted ventilation in participants with a clinical diagnosis of ALS, independent of the reported outcomes. We included comparisons with no intervention or the best standard care.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-08-31 14:31:17 +0100" MODIFIED_BY="Ruth Brassington">
<P>For the original review, four review authors independently selected studies for assessment. Two review authors reviewed searches for this update. All review authors independently extracted data from the full text of selected studies and assessed the risk of bias in studies that met the inclusion criteria. We attempted to obtain missing data where possible. We planned to collect adverse event data from the included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-08-31 14:56:34 +0100" MODIFIED_BY="Ruth Brassington">
<P>For the original Cochrane Review, the review authors identified two RCTs involving 54 participants with ALS receiving NIV. There were no new RCTs or quasi-RCTs at the first update. One new RCT was identified in the second update but was excluded for the reasons outlined below.</P>
<P>Incomplete data were available for one published study comparing early and late initiation of NIV (13 participants). We contacted the trial authors, who were not able to provide the missing data. The conclusions of the review were therefore based on a single study of 41 participants comparing NIV with standard care. Lack of (or uncertain) blinding represented a risk of bias for participant- and clinician-assessed outcomes such as quality of life, but it was otherwise a well-conducted study with a low risk of bias.</P>
<P>The study provided moderate-quality evidence that overall median survival was significantly different between the group treated with NIV and the standard care group. The median survival in the NIV group was 48 days longer (219 days compared to 171 days for the standard care group (estimated 95% confidence interval 12 to 91 days, P = 0.0062)). This survival benefit was accompanied by an enhanced quality of life. On subgroup analysis, in the subgroup with normal to moderately impaired bulbar function (20 participants), median survival was 205 days longer (216 days in the NIV group versus 11 days in the standard care group, P = 0.0059), and quality of life measures were better than with standard care (low-quality evidence). In the participants with poor bulbar function (21 participants), NIV did not prolong survival or improve quality of life, although there was significant improvement in the mean symptoms domain of the Sleep Apnea Quality of Life Index by some measures. Neither trial reported clinical data on intervention-related adverse effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-08-31 14:53:33 +0100" MODIFIED_BY="Ruth Brassington">
<P>Moderate-quality evidence from a single RCT of NIV in 41 participants suggests that it significantly prolongs survival, and low-quality evidence indicates that it improves or maintains quality of life in people with ALS. Survival and quality of life were significantly improved in the subgroup of people with better bulbar function, but not in those with severe bulbar impairment. Adverse effects related to NIV should be systematically reported, as at present there is little information on this subject. More RCT evidence to support the use of NIV in ALS will be difficult to generate, as not offering NIV to the control group is no longer ethically justifiable. Future studies should examine the benefits of early intervention with NIV and establish the most appropriate timing for initiating NIV in order to obtain its maximum benefit. The effect of adding cough augmentation techniques to NIV also needs to be investigated in an RCT. Future studies should examine the health economics of NIV. Access to NIV remains restricted in many parts of the world, including Europe and North America. We need to understand the factors, personal and socioeconomic, that determine access to NIV.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-09-18 14:57:59 +0100" MODIFIED_BY="Sophie Maprayil">
<BACKGROUND MODIFIED="2017-09-18 14:51:14 +0100" MODIFIED_BY="Sophie Maprayil">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a fatal neurodegenerative disease characterised by loss of upper and lower motor neurons in the brain and spinal cord (<LINK REF="REF-Brooks-1994" TYPE="REFERENCE">Brooks 1994</LINK>; <LINK REF="REF-Brooks-2000" TYPE="REFERENCE">Brooks 2000</LINK>). The incidence of ALS is 1 to 2 per 100,000 of the population, and the age-specific incidence and mortality rates peak at 55 to 75 years (<LINK REF="REF-Worms-2001" TYPE="REFERENCE">Worms 2001</LINK>). The average life expectancy is two to three years from the onset of symptoms, although 10% of people with ALS may survive for 10 years or more (<LINK REF="REF-Haverkamp-1995" TYPE="REFERENCE">Haverkamp 1995</LINK>; <LINK REF="REF-Turner-2003" TYPE="REFERENCE">Turner 2003</LINK>). Death usually results from respiratory failure due to denervation weakness in respiratory muscles. Respiratory muscle function at any time point during the disease trajectory is the most important predictor of survival and an important predictor of quality of life (<LINK REF="REF-Bach-1995" TYPE="REFERENCE">Bach 1995</LINK>; <LINK REF="REF-Haverkamp-1995" TYPE="REFERENCE">Haverkamp 1995</LINK>; <LINK REF="REF-Vitacca-1997" TYPE="REFERENCE">Vitacca 1997</LINK>; <LINK REF="REF-Stambler-1998" TYPE="REFERENCE">Stambler 1998</LINK>; <LINK REF="REF-Fitting-1999" TYPE="REFERENCE">Fitting 1999</LINK>; <LINK REF="REF-Chaudri-2000" TYPE="REFERENCE">Chaudri 2000</LINK>; <LINK REF="REF-Bourke-2001" TYPE="REFERENCE">Bourke 2001</LINK>; <LINK REF="REF-Lyall-2001a" TYPE="REFERENCE">Lyall 2001a</LINK>; <LINK REF="REF-Varrato-2001" TYPE="REFERENCE">Varrato 2001</LINK>; <LINK REF="REF-Lechtzin-2002" TYPE="REFERENCE">Lechtzin 2002</LINK>). Measures of respiratory muscle strength (e.g. forced vital capacity and sniff nasal inspiratory pressure) are useful in monitoring the progression of respiratory muscle weakness, but no single test of respiratory function can reliably predict the onset of respiratory failure. Furthermore, respiratory function tests have limitations in people with bulbar weakness, who cannot blow effectively (<LINK REF="REF-Lyall-2001a" TYPE="REFERENCE">Lyall 2001a</LINK>).</P>
<P>Assisted ventilation has long been used to support ventilation in respiratory failure (<LINK REF="REF-Annane-2014" TYPE="REFERENCE">Annane 2014</LINK>). Assisted ventilation can be provided by invasive (tracheostomy ventilation (TV)) and non-invasive (NIV) means. Tracheostomy ventilation can prolong survival for many years (<LINK REF="STD-Bach-1993" TYPE="STUDY">Bach 1993</LINK>; <LINK REF="STD-Cazzolli-1996" TYPE="STUDY">Cazzolli 1996</LINK>), but it is resource-intensive and risks ventilator entrapment, which exacts a significant emotional toll on people with ALS and their carers (<LINK REF="REF-Moss-1993" TYPE="REFERENCE">Moss 1993</LINK>; <LINK REF="STD-Cazzolli-1996" TYPE="STUDY">Cazzolli 1996</LINK>; <LINK REF="REF-Moss-1996" TYPE="REFERENCE">Moss 1996</LINK>). Tracheostomy ventilation may prolong life in the face of increasing disability and dependency, and hence quality of life may not be sustained. Nevertheless, people affected by ALS are increasingly aware of this option. Tracheostomy ventilation in ALS is not encouraged in Europe and North America (<LINK REF="REF-Hayashi-1997" TYPE="REFERENCE">Hayashi 1997</LINK>; <LINK REF="REF-Borasio-1998" TYPE="REFERENCE">Borasio 1998</LINK>; <LINK REF="REF-Yamaguchi-2001" TYPE="REFERENCE">Yamaguchi 2001</LINK>). In Japan, however, TV is the predominant form of ventilation offered to people with ALS, and the cost is fully covered by the government and medical insurance (<LINK REF="REF-Kawata-2008" TYPE="REFERENCE">Kawata 2008</LINK>).</P>
<P>Non-invasive ventilation is another option for treating respiratory failure in people with ALS. Non-invasive ventilation utilises a face or nasal mask and a volume-cycled or bilevel pressure-limited ventilator to provide an intermittent positive pressure to support ventilation. Until the turn of the century, the use of NIV varied greatly across North America and Europe (<LINK REF="REF-Melo-1999" TYPE="REFERENCE">Melo 1999</LINK>; <LINK REF="REF-Borasio-2001" TYPE="REFERENCE">Borasio 2001</LINK>; <LINK REF="REF-Bradley-2001" TYPE="REFERENCE">Bradley 2001</LINK>; <LINK REF="STD-Cedarbaum-2001" TYPE="STUDY">Cedarbaum 2001</LINK>; <LINK REF="REF-Chio-2001" TYPE="REFERENCE">Chio 2001</LINK>; <LINK REF="REF-Bourke-2002" TYPE="REFERENCE">Bourke 2002</LINK>). Evidence from several retrospective and some prospective studies indicated that NIV may be associated with gain in survival (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Aboussouan-1997" TYPE="STUDY">Aboussouan 1997</LINK>; <LINK REF="STD-Kleopa-1999" TYPE="STUDY">Kleopa 1999</LINK>; <LINK REF="REF-Bach-2002" TYPE="REFERENCE">Bach 2002</LINK>), improved quality of life (<LINK REF="REF-Hein-1997" TYPE="REFERENCE">Hein 1997</LINK>; <LINK REF="REF-Hein-1999" TYPE="REFERENCE">Hein 1999</LINK>; <LINK REF="REF-Aboussouan-2001" TYPE="REFERENCE">Aboussouan 2001</LINK>; <LINK REF="REF-Bourke-2001" TYPE="REFERENCE">Bourke 2001</LINK>; <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Lyall-2001b" TYPE="STUDY">Lyall 2001b</LINK>), and improved cognitive function (<LINK REF="STD-Newsom_x002d_Davis-2001" TYPE="STUDY">Newsom-Davis 2001</LINK>). People with ALS who have little or no bulbar muscle weakness may tolerate NIV better than those with significant bulbar involvement (<LINK REF="STD-Cazzolli-1996" TYPE="STUDY">Cazzolli 1996</LINK>; <LINK REF="STD-Aboussouan-1997" TYPE="STUDY">Aboussouan 1997</LINK>). In the absence of a randomised controlled trial (RCT), uncertainties remained over the benefits and unwanted effects of TV and NIV.</P>
<P>
<LINK REF="REF-Annane-2014" TYPE="REFERENCE">Annane 2014</LINK>, a Cochrane Review of nocturnal mechanical ventilation for a mixed group of people with chronic hypoventilation, identified eight randomised trials, three of which involved people with ALS. This review concluded that nocturnal ventilation may relieve chronic hypoventilation-related symptoms and prolong survival, but that the quality of the studies was poor and the benefit of long-term mechanical ventilation should be confirmed in further trials. The evidence was thought to be strongest for NIV in people with ALS.</P>
<P>Over the past few years, the use of NIV in ALS has greatly increased (<LINK REF="REF-O_x0027_Neill-2012" TYPE="REFERENCE">O'Neill 2012</LINK>). An RCT evaluated the effects of NIV on survival and quality of life in people with ALS (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>). The National Institute for Health and Care Excellence UK (NICE) has published guidelines on the use of NIV in people with ALS (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). The aim of this review was to assimilate the evidence for mechanical ventilation in ALS and to assess the benefits and unwanted effects of TV and NIV. The conclusions of <LINK REF="REF-Radunovic-2009" TYPE="REFERENCE">Radunovic 2009</LINK>, the original version of this review, were based on the results of this single study of 41 participants (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>), as the other available study provided no usable data (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>). For this 2017 update, we identified no new RCTs or quasi-RCTs.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-08-31 14:33:30 +0100" MODIFIED_BY="Ruth Brassington">
<P>To assess the effects of mechanical ventilation (tracheostomy-assisted ventilation and non-invasive ventilation) on survival, functional measures of disease progression, and quality of life in ALS, and to evaluate adverse events related to the intervention.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-09-18 14:51:32 +0100" MODIFIED_BY="Sophie Maprayil">
<SELECTION_CRITERIA MODIFIED="2017-08-31 14:34:12 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES MODIFIED="2017-08-31 14:33:39 +0100" MODIFIED_BY="Ruth Brassington">
<P>All RCTs and quasi-RCTs involving NIV or TV. Quasi-RCTs are trials where treatment allocation was intended to be random but may have been biased (e.g. alternate allocation or allocation according to the day of the week). We selected studies independently of reported outcomes.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-08-31 14:33:40 +0100" MODIFIED_BY="Ruth Brassington">
<P>People with a clinical diagnosis of ALS/MND (pure mixed upper motor neuron and lower motor neuron degeneration with supportive electromyogram) according to the El Escorial criteria (<LINK REF="REF-Brooks-1994" TYPE="REFERENCE">Brooks 1994</LINK>; <LINK REF="REF-Brooks-2000" TYPE="REFERENCE">Brooks 2000</LINK>), at any stage of disease and with any clinical pattern of the condition (e.g. bulbar and limb onset). Subgroups of interest were participants with or without significant bulbar symptoms as categorised by the authors of the papers reviewed.</P>
<P>We did not consider trials of mixed neuromuscular or chest wall conditions, which are included in a separate review (<LINK REF="REF-Annane-2014" TYPE="REFERENCE">Annane 2014</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-08-31 14:33:42 +0100" MODIFIED_BY="Ruth Brassington">
<P>All forms of NIV (irrespective of pressure settings and timings) and TV, compared to no intervention or the best standard care.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-08-31 14:34:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Our outcomes were not selection criteria, but rather a list of outcomes of interest within included studies.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-08-31 14:33:43 +0100" MODIFIED_BY="Ruth Brassington">
<P>The primary outcome was overall survival after initiation of assisted ventilation, as assessed by a pooled hazard ratio using life table/Cox regression methods to combine disparate periods of observation from all studies. This would have been supplemented where possible by pooled estimates of the 75%, 50% (median) survival times and confidence intervals (CIs). This is to allow for the situation where the proportional hazards assumption, necessary for Cox regression, has not been met.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-08-31 14:34:12 +0100" MODIFIED_BY="Ruth Brassington">
<OL>
<LI>Survival at one month and six months or longer.</LI>
<LI>Quality of life assessed using validated health status questionnaires, e.g. 36-Item Short Form Health Survey (SF-36) at one month and six months or longer (<LINK REF="STD-Lyall-2001b" TYPE="STUDY">Lyall 2001b</LINK>).</LI>
<LI>Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (<LINK REF="REF-ALSFRS-1996" TYPE="REFERENCE">ALSFRS 1996</LINK>; <LINK REF="REF-Cedarbaum-1999" TYPE="REFERENCE">Cedarbaum 1999</LINK>), Norris (<LINK REF="REF-Norris-1974" TYPE="REFERENCE">Norris 1974</LINK>), or Appel scales at one month and six months or longer (<LINK REF="REF-Haverkamp-1995" TYPE="REFERENCE">Haverkamp 1995</LINK>).</LI>
<LI>The proportion of people experiencing adverse events related to mechanical ventilation. We would have considered adverse events in two categories. The first category would have included the proportion of participants experiencing any adverse event attributed to ventilation (e.g. fistulae, pneumothorax, bleeding, local infection, hospitalisation, or death), and the second category would have included participants experiencing severe complications of mechanical ventilation, including life-threatening episodes, prolonged hospitalisation, and death.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-09-18 14:51:22 +0100" MODIFIED_BY="Sophie Maprayil">
<P>We searched the following databases:</P>
<UL>
<LI>the Cochrane Neuromuscular Specialised Register (30 January 2017) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) (30 January 2017, in the Cochrane Register of Studies Online (CRSO)) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>MEDLINE (1966 to 30 January 2017) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
<LI>Embase (1980 to 30 January 2017) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>);</LI>
<LI>CINAHL Plus (1937 to 30 January 2017) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>);</LI>
<LI>AMED (Allied and Complementary Medicine Database) (1985 to 30 January 2017) (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</LI>
</UL>
<P>We also searched for ongoing or unpublished trials on 1 February 2017 in:</P>
<UL>
<LI>the US National Institutes of Health trials registry ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>);</LI>
<LI>the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>) (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>).</LI>
</UL>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-09-18 14:51:32 +0100" MODIFIED_BY="Sophie Maprayil">
<STUDY_SELECTION MODIFIED="2017-08-31 14:56:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>For the original review, all four review authors (AR, DA, KJ, NM) checked titles and abstracts identified by the searches for RCTs or quasi-RCTs, and two review authors (MKR and DA) reviewed the searches for the update. We obtained the full texts of all potentially relevant studies, which the review authors independently assessed.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-08-31 14:34:51 +0100" MODIFIED_BY="Ruth Brassington">
<P>All review authors independently extracted data onto a specially designed form. We tried to obtain missing or additional data from the study authors wherever possible. For our primary outcome, overall survival after initiation of assisted ventilation, we planned to extract hazard ratios with standard errors or confidence intervals (CIs), or median survival times with 95% CIs, or the numbers required to construct a life table, for example the numbers surviving or failing to survive after initiation of assisted ventilation for a sequence of specified time intervals.</P>
<P>In any studies requiring translation, the translator would extract data directly onto a data extraction form. If possible, the review authors would have checked any numerical data extraction against the study report.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-08-31 14:35:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>All review authors decided which trials met the inclusion criteria for the review and assessed the risk of bias for the included studies. Any disagreements about inclusion were resolved by discussion between review authors. We completed a 'Risk of bias' assessment for all included studies according to the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We evaluated random sequence generation, allocation concealment, blinding (participants and personnel, and outcome assessors), incomplete outcome data, selective outcome reporting, and other sources of bias. We then made a judgement on each of these criteria of 'high risk', 'low risk', or 'unclear risk', where 'unclear risk' indicates an unclear or unknown risk of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-09-18 14:51:32 +0100" MODIFIED_BY="Sophie Maprayil">
<P>In <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK> we have reported in full methods that the review authors will follow if more trials become available in the future and meta-analysis becomes possible.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>We created a 'Summary of findings' table using the following outcomes.</P>
<OL>
<LI>Length of survival following initiation of mechanical ventilation.</LI>
<LI>Quality of life.</LI>
<LI>Adverse events.</LI>
</OL>
<P>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used footnotes to justify all decisions to down- or upgrade the quality of the evidence and made comments to aid readers' understanding of the review where necessary.</P>
<P>We reported summary scores for quality of life outcomes. We reported the median days at which quality of life remained above 75% of baseline in the 'Summary of findings' table, as raw scores were not available, and of the two quality of life analyses reported in <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>, this is more easily interpreted.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2017-08-31 14:35:14 +0100" MODIFIED_BY="Ruth Brassington">
<P>We contacted investigators in order to verify key study characteristics and to obtain missing numerical outcome data.</P>
</MISSING_DATA>
<BIAS_ASSESSMENT MODIFIED="2017-08-31 14:35:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>Our search strategies were comprehensive. For this update, we searched trials registries to identify any completed but unpublished trials.</P>
<P>We considered non-randomised evidence related to adverse events, cost, and cost-effectiveness of different forms of mechanical ventilation in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
</BIAS_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-09-18 14:51:46 +0100" MODIFIED_BY="Sophie Maprayil">
<STUDY_DESCRIPTION MODIFIED="2017-09-18 14:51:46 +0100" MODIFIED_BY="Sophie Maprayil">
<SEARCH_RESULTS MODIFIED="2017-08-31 14:35:17 +0100" MODIFIED_BY="Ruth Brassington">
<P>The updated database searches for this update produced the following results: MEDLINE 224 (78 new references), Embase 190 (92 new), AMED 6 (1 new), CINAHL 11 (2 new), Cochrane Neuromuscular Specialised Register 66 (33 new), and CENTRAL 63 (37 new). We reviewed 242 new references from database searches for this update, with 217 after deduplication, but none were eligible for inclusion. We also reviewed 77 records in ClinicalTrials.gov and 2 records in WHO ICTRP. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a flow chart of the study selection process.</P>
<P>We also searched the Database of Abstracts of Reviews of Effects (4 references), Health Technology Assessment database (4 references), and NHS Economic Evaluation Database (3 references) for information for inclusion in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-08-31 14:35:24 +0100" MODIFIED_BY="Ruth Brassington">
<P>All review authors agreed on the inclusion of two studies (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>).</P>
<P>The first study was a prospective randomised three-month study in three ALS centres in the USA (<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>). The study included 20 people with ALS (no age or sex provided), of whom 13 were randomised when overnight oximetry studies documented oxygen saturation below 90% for at least one cumulative minute throughout the duration of the study (a minimum of six hours) and the individual had at least two significant symptoms of nocturnal hypoventilation. There were two groups: an early group where the participants were started immediately on NIV (seven participants) and a late group (six participants) in whom NIV was initiated when forced vital capacity (FVC) was less than 50% predicted. The report provided no demographic characteristics for the participants. The effects of NIV on ALSFRS respiratory version, Pulmonary Symptom Scale, and SF-36 were estimated. No survival data were available from this study.</P>
<P>The second study was an RCT performed in a single ALS centre in the UK. It included 92 participants, of whom 41 met the criteria for randomisation (orthopnoea or maximum inspiratory pressures less than 60% or symptomatic hypercapnia, or both) and were followed up for at least 12 months or until death (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>). Random allocation was computer generated by minimisation, a process that allows all significant prognostic factors to be included in the model. Twenty-two participants were assigned to the NIV group and 19 participants to the standard care group. Demographic and functional characteristics of the participants in the two groups were similar at randomisation (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The effect of NIV on survival and quality of life outcome domains (e.g. SF-36 and the Sleep Apnea Quality of Life Index (SAQLI)) was estimated in the whole cohort but also in the subgroups of participants with and without severe impairment of bulbar function. Trialists defined severe impairment as a score of three or less on a simple six-point assessment scale.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-09-18 14:51:46 +0100" MODIFIED_BY="Sophie Maprayil">
<P>We excluded one study that was terminated early due to problems recruiting participants (<LINK REF="STD-Perez-2003" TYPE="STUDY">Perez 2003</LINK>). We excluded <LINK REF="STD-Pinto-2003" TYPE="STUDY">Pinto 2003</LINK> as it used historical controls. One study was a controlled study of exercise in people with ALS with respiratory insufficiency (<LINK REF="STD-Pinto-1999" TYPE="STUDY">Pinto 1999</LINK>). One study was an anecdotal study (<LINK REF="STD-Sivak-1982" TYPE="STUDY">Sivak 1982</LINK>). Twelve studies were retrospective (<LINK REF="STD-Goulon-1989" TYPE="STUDY">Goulon 1989</LINK>; <LINK REF="STD-Kamimoto-1989" TYPE="STUDY">Kamimoto 1989</LINK>; <LINK REF="STD-Bach-1993" TYPE="STUDY">Bach 1993</LINK>; <LINK REF="STD-Cazzolli-1996" TYPE="STUDY">Cazzolli 1996</LINK>; <LINK REF="STD-David-1997" TYPE="STUDY">David 1997</LINK>; <LINK REF="STD-Buhr_x002d_Schinner-1999" TYPE="STUDY">Buhr-Schinner 1999</LINK>; <LINK REF="STD-Kleopa-1999" TYPE="STUDY">Kleopa 1999</LINK>; <LINK REF="STD-Saito-1999" TYPE="STUDY">Saito 1999</LINK>; <LINK REF="STD-Cedarbaum-2001" TYPE="STUDY">Cedarbaum 2001</LINK>; <LINK REF="STD-Winterholler-2001" TYPE="STUDY">Winterholler 2001</LINK>; <LINK REF="STD-Lo-Coco-2007" TYPE="STUDY">Lo Coco 2007</LINK>; <LINK REF="STD-Shoesmith-2007" TYPE="STUDY">Shoesmith 2007</LINK>), of which only <LINK REF="STD-Kleopa-1999" TYPE="STUDY">Kleopa 1999</LINK> had a control group.  Six studies were non-randomised prospective observational studies (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Aboussouan-1997" TYPE="STUDY">Aboussouan 1997</LINK>; <LINK REF="STD-Lyall-2001b" TYPE="STUDY">Lyall 2001b</LINK>; <LINK REF="STD-Newsom_x002d_Davis-2001" TYPE="STUDY">Newsom-Davis 2001</LINK>; <LINK REF="STD-Lo-Coco-2006" TYPE="STUDY">Lo Coco 2006</LINK>; <LINK REF="STD-Mustfa-2006" TYPE="STUDY">Mustfa 2006</LINK>). <LINK REF="STD-Berlowitz-2016" TYPE="STUDY">Berlowitz 2016</LINK> was a cohort study examining the effects of NIV on pulmonary function decline and survival across MND/ALS phenotypes.</P>
<P>
<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK> was a single-centre study in Portugal that included 20 consecutive participants with bulbar features and probable or definite ALS according to El Escorial criteria. The first 10 participants were treated with oxygen, bronchodilators, and physiotherapy. The following 10 participants were submitted to bilevel positive airway pressure. Two participants were excluded, one in the first group because the participant had tracheostomy, and the other in the second group for refusing the treatment. Despite the limitation of small sample size, the study demonstrated a significant improvement in total survival time (P &lt; 0.004) and in the survival from the onset of diurnal gas exchange disorder (P &lt; 0.006). Although it was a controlled trial, participants were not randomised, and hence selection bias cannot be excluded.</P>
<P>A 2016 study looked at the early initiation of NIV within a sham and an interventional arm (<LINK REF="STD-Jacobs-2016" TYPE="STUDY">Jacobs 2016</LINK>). It essentially compared 4 cm continuous positive airway pressure against bilevel ventilation at 8/4 cmH<SUB>2</SUB>O at a stage at which NIV would not normally be used. The two groups used NIV (or sham) for only 2.0 hours/day and 3.3 hours/day, respectively. The reported outcome was decline in percentage predicted FVC during the follow-up period. Once both groups reached the time when they met the standard criteria for starting NIV, both groups were offered NIV. There was no difference in the survival of the two groups. The review authors considered that the main objective of this study was to assess the benefits of early initiation of NIV, and the trial did not evaluate NIV against no intervention, therefore we could not consider this data as complementary to the objectives of this review.</P>
<P>We excluded four apparently unpublished trials in clinical trials registries that compared different settings, modes, or timings of NIV (<LINK REF="STD-NCT00537446" TYPE="STUDY">NCT00537446</LINK>; <LINK REF="STD-NCT00560287" TYPE="STUDY">NCT00560287</LINK>; <LINK REF="STD-NCT01363882" TYPE="STUDY">NCT01363882</LINK>; <LINK REF="STD-NCT01641965" TYPE="STUDY">NCT01641965</LINK>). We excluded an ongoing trial in which different modes of ventilation were to be compared (<LINK REF="STD-NCT01746381" TYPE="STUDY">NCT01746381</LINK>). We enquired about two further registry entries from investigators. The contact person for <LINK REF="STD-NCT00958048" TYPE="STUDY">NCT00958048</LINK> informed us that because participants were not willing to be randomised, investigators converted the trial to an observational study, which was not eligible for this review. An investigator of <LINK REF="STD-NCT00386464" TYPE="STUDY">NCT00386464</LINK> reported that the trial had recruitment problems and was neither completed nor published.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-08-31 14:36:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>For a 'Risk of bias' summary see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2017-08-31 14:35:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>Allocation was adequately concealed in both included studies. <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> performed centralised randomisation; random allocation was computer generated by the process of minimisation. Although the <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> paper gives no data for allocation concealment, the study authors informed us that an independent statistician performed randomisation by preparing two sets of random assignment in blocks of four, which were then allocated to each centre.</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-08-31 14:35:55 +0100" MODIFIED_BY="Ruth Brassington">
<P>Blinding of participants was not possible in the included studies, as it was not possible to blind delivery of NIV. Outcome assessors were blinded in <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; no information was given in <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> as to whether outcome assessors were blinded to knowledge of allocation intervention.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-08-31 14:35:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> provided data on only six participants from the early-intervention group. The outcome of one randomised participant was not clear, and the paper provided no data for the late-intervention group. We noted no obvious attrition bias in <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>. Thirteen participants withdrew during surveillance, but none withdrew after randomisation, and all participants were followed up until the end of the study or death.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-08-31 14:36:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> was free of the suggestion of selective outcome reporting, as the study protocol was available, and the trial authors reported all primary and secondary outcomes in the prespecified way. No study protocol was available for <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>. The results of <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> were intended to be used as preliminary data, but unfortunately the investigators did not secure funding for a subsequent study.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-08-31 14:36:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>In <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>, trial authors did not define nocturnal hypoventilation according to the universally accepted criteria; they accepted oxygen desaturation below 90% for at least one cumulative minute as evidence of nocturnal hypoventilation. Nocturnal oximetry showing oxygen desaturation below 88% for at least five consecutive minutes or oxygen saturation below 90% for more than 5% of sleep time are considered sufficient to initiate NIV (<LINK REF="REF-Mehta-2001" TYPE="REFERENCE">Mehta 2001</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-08-31 14:36:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>Both included studies used NIV.</P>
<P>
<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> provided insufficient data to be included in meta-analyses, and this prevented pooled analysis of either primary or secondary outcome measures. Our review was therefore based on the results of one study, <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>. Neither were we able to obtain individual participant data or life tables from the <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> trialists.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>
<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> showed that the overall median survival after initiation of assisted ventilation was significantly different between the NIV and standard care groups (P = 0.0062). The median survival for the NIV group participants was 48 days longer than the standard care group participants (219 days compared to 171 days). The published information did not provide a 95% confidence interval (CI) for the median survival difference (48 days) or for our secondary outcomes. We were able to derive approximate CIs from P values and median survival estimates under an assumption that median survival follows a lognormal distribution. A statistical method based on a lognormal survival model gave the following estimates for the 95% CI: 12 to 91 days for the estimated 48-day survival difference (private communication from statistical referee Dan Moore).</P>
<P>The overall median survival of the subgroup with better (good or moderately impaired) bulbar function was also significantly different in the NIV group (P = 0.0059), with NIV group participants surviving 205 days longer than the standard care group participants (median 216 days in NIV group versus 11 days in the standard care group). </P>
<P>In participants with poor bulbar function, NIV did not confer survival advantage (P = 0.92), with an overall median survival for NIV group participants of 39 days less than the standard care group (222 versus 261 days). We considered the quality of the survival evidence as moderate, as it was based on a single RCT (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.  Survival at one or six months or longer</HEADING>
<P>No data were available for survival at one and six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.  Quality of life assessed using validated health status questionnaires at one and six months or longer</HEADING>
<P>No data were available at one and six months for either study.</P>
<P>
<LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> did not systematically report quality of life data.</P>
<P>
<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> reported the time SAQLI and SF-36 scores were maintained above 75% of pre-randomisation assessment, and time-weighted mean improvements in SF-36 and sleep-related SAQLI (the median (range) values of AUC (area under the curve) above baseline divided by time from randomisation to death). We have reported here the summary scores but also provide the SAQLI symptoms score, which the <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> trialists designated as primary.</P>
<SUBSECTION>
<HEADING LEVEL="6">Summary scores</HEADING>
<P>We were unable to calculate mean difference and 95% CI from the available data. Based on interpretation of P values from two-sided tests of significance (0.05 significance level) on intention-to-treat data, the median time after initiation of assisted ventilation that quality of life was maintained above 75% of the baseline, based on the SF-36 mental component summary (MCS), Physical Component Summary (PCS), and the SAQLI score, was significantly longer with NIV than standard care in the group as a whole and in the subgroup with normal and moderately impaired bulbar function. In participants with poor bulbar function, NIV conferred no significant benefit using these measures. For numerical data, see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>The time-weighted mean improvement in the SF-36 MCS score and the sleep-related SAQLI were found to be significantly greater in the NIV group than the standard care group in the whole cohort (n = 41) and in the participants with better bulbar function (n = 20), but not in those with poor bulbar function (n = 21). The time-weighted mean improvement in the SF-36 PCS was greater in the participants with better bulbar function, but not in the whole group or in the subgroup with poor bulbar function. For numerical data, see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other primary quality of life outcomes in the included study</HEADING>
<P>
<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> chose the SF-36 MCS (reported above) and the sleep-related SAQLI symptoms domain as primary quality of life outcome measures, based on the results of a pilot study. The study report and the trial protocol do not indicate whether these outcomes were prespecified as primary.</P>
<P>The study showed that the median time the SAQLI symptoms domain score was maintained above 75% of the baseline after initiation of NIV was significantly longer with NIV than with standard care in the group as a whole and in the subgroup with normal and moderately impaired bulbar function. In participants with poor bulbar function, NIV conferred no significant benefit in maintaining the SAQLI symptoms score above 75% of baseline. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>A significant difference in time-weighted mean improvement of SAQLI between the NIV and standard care group was present in the group as a whole and in both subgroups. See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2a. Quality of life median values at one and six months</HEADING>
<P>No data were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Functional rating scale at one or six months or longer</HEADING>
<P>No data were available for the ALSFRS to be analysed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3a. Functional rating scales median values</HEADING>
<P>No data were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Proportion experiencing adverse events related to mechanical ventilation</HEADING>
<P>Neither <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> nor <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> reported adverse events related to mechanical ventilation.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-09-18 14:57:59 +0100" MODIFIED_BY="Sophie Maprayil">
<P>Two reports of RCTs of nocturnal mechanical ventilation in ALS were available for this review. Both trials employed NIV. Since only one of the reports provided data suitable for analysis (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>), we were not able to perform a meta-analysis.</P>
<P>
<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> was designed to assess the effect of NIV on survival and quality of life in people with ALS. The study provided moderate-quality evidence that NIV prolongs median survival, and low-quality evidence that it maintains quality of life in people with ALS overall. The benefit of NIV was striking in the subgroup of participants with better (normal or moderately impaired) bulbar function, but it is, however, important to note that six of nine participants in the standard group died within two weeks of randomisation, thus probably overestimating the effect of NIV in this subgroup of people with ALS. Non-invasive ventilation did not prolong survival in people with ALS who had severe bulbar dysfunction, but did improve sleep-related symptoms in this subgroup.</P>
<P>Despite the above shortcomings, <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> has shown that NIV significantly improves quality of life over standard care, prolonging life for longer than is reported with riluzole (<LINK REF="REF-Miller-2012" TYPE="REFERENCE">Miller 2012</LINK>). The study has confirmed previous observations from non-randomised trials of survival advantage and improved quality of life in people with ALS who start and can tolerate NIV at the onset of respiratory impairment (<LINK REF="STD-Bach-1993" TYPE="STUDY">Bach 1993</LINK>; <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Aboussouan-1997" TYPE="STUDY">Aboussouan 1997</LINK>; <LINK REF="STD-Kleopa-1999" TYPE="STUDY">Kleopa 1999</LINK>; <LINK REF="STD-Lyall-2001b" TYPE="STUDY">Lyall 2001b</LINK>). It is unlikely that there will be further RCTs of NIV in unselected cohorts of people with ALS. In the view of the review authors, evidence from <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> supports the belief that NIV is a major advance in the management of ALS, and it would be unethical in future trials not to offer NIV to people with ALS who have symptoms of nocturnal hypoventilation. The evidence supports benefit from NIV in people with ALS. The National Institute for Health and Care Excellence (NICE) carried out a cost-effectiveness analysis using the Markov model and concluded that the use of NIV in the management of people with ALS represents a cost-effective use of resources (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>).</P>
<P>A UK-wide survey demonstrated that the provision of NIV to people with ALS is increasing (<LINK REF="REF-O_x0027_Neill-2012" TYPE="REFERENCE">O'Neill 2012</LINK>). A study has also reported on the obstacles people with ALS experience in using NIV and how to address them (<LINK REF="REF-Baxter-2013a" TYPE="REFERENCE">Baxter 2013a</LINK>). Some people with ALS are unable to tolerate NIV and decide to discontinue its use. Careful attention to secretion management, humidification, and comfortable interfaces may improve compliance with NIV. Detailed explanation to the patient along with emphasis of benefits may pre-empt difficulties. A qualitative study has addressed concerns about the use of NIV in the terminal phase of the disease (<LINK REF="REF-Baxter-2013b" TYPE="REFERENCE">Baxter 2013b</LINK>). This study did not find the use of NIV in the last days of life to be associated with any adverse effects. The authors advised rapid withdrawal rather than gradual weaning when patients express a wish to discontinue NIV. The study concluded that patients' wishes should guide the use of NIV at the end of life. Another study investigated the impact of NIV on the family carer and concluded that NIV had no significant impact on carer burden (<LINK REF="REF-Baxter-2013c" TYPE="REFERENCE">Baxter 2013c</LINK>).</P>
<P>Conclusions from <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> cannot be extended to people with ALS who do not have respiratory symptoms. It has been suggested that early treatment with NIV may offer a survival benefit above that demonstrated in <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>. There is some evidence from non-controlled studies that early NIV improves survival and reduces decline of FVC in ALS (<LINK REF="REF-Carratu-2009" TYPE="REFERENCE">Carratu 2009</LINK>). <LINK REF="STD-NCT01641965" TYPE="STUDY">NCT01641965</LINK> is an ongoing RCT evaluating the impact of early NIV in people with ALS who have mild respiratory involvement. <LINK REF="STD-Jacobs-2016" TYPE="STUDY">Jacobs 2016</LINK> is a pilot study that aimed to determine the feasibility of conducting a randomised, double-blind, placebo-controlled trial of early NIV versus sham NIV in people with ALS. The study was not powered to assess clinical outcomes.</P>
<P>Non-invasive ventilation settings may require titration with disease progression. A randomised trial is evaluating the use of polysomnography in guiding the initiation and further titration of NIV therapy during the course of the disease (<LINK REF="STD-NCT01363882" TYPE="STUDY">NCT01363882</LINK>). Different ventilator modes and settings are to be assessed in two NIV trials in people with ALS. The Italian multicentre randomised NIV study was designed to evaluate clinical efficacy, the participants' tolerance and quality of life and the frequency of changing settings in people with ALS who are undergoing NIV with pressure support ventilation or volume-assisted ventilation (<LINK REF="STD-NCT00560287" TYPE="STUDY">NCT00560287</LINK>). However, this trial is compromised due to incomplete outcome data. The Columbia University study is designed to measure difference in pulmonary function and respiratory muscle pressure testing, gas exchange, and subjective dyspnoea between baseline and two different ventilator modes (high- and low-level non-invasive positive pressure ventilation) (<LINK REF="STD-NCT00537446" TYPE="STUDY">NCT00537446</LINK>). Another study is evaluating the use of an Intelligent Volume-Assured Pressure Support (iVAPS) ventilator in ALS (<LINK REF="STD-NCT01746381" TYPE="STUDY">NCT01746381</LINK>). Most of these studies are not eligible for this review, which focuses on NIV compared to no NIV or standard care. They may, however, inform the best pressure settings of NIV and the ideal time of its initiation to obtain the maximum benefit.</P>
<P>Another Cochrane Review of nocturnal ventilation for daytime hypoventilation in neuromuscular and chest wall disorders concluded, while noting several methodological limitations, that mechanical ventilation is associated with survival benefit in MND (<LINK REF="REF-Annane-2014" TYPE="REFERENCE">Annane 2014</LINK>). This conclusion was based on three trials (<LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK>; <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK>; <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>). <LINK REF="STD-Jackson-2001" TYPE="STUDY">Jackson 2001</LINK> is included in this review, but we consider it to be at high risk of bias due to selective reporting. We excluded <LINK REF="STD-Pinto-1995" TYPE="STUDY">Pinto 1995</LINK> as we considered it a non-randomised controlled study. Another review on the management of respiratory problems in neurodegenerative disease concluded that the evidence to support the role of NIV was strongest for MND, although the evidence itself was weak (<LINK REF="REF-Jones-2012" TYPE="REFERENCE">Jones 2012</LINK>).</P>
<P>A limitation of the evidence in this review is that it was based on a single RCT with 41 participants, and hence we assessed the quality of the evidence as moderate for improvement in survival. However, findings of this trial are consistent with the findings of several other studies, which together offer strong support for the benefit of NIV for people with ALS in respiratory failure. We contacted investigators of registered but unreported trials to determine whether they had been abandoned or were completed but unpublished. We did not identify any study that addressed the adverse effects of NIV.</P>
<P>The review protocol did not define the quality of life outcome in detail. The protocol and study report of <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK> do not state whether the primary quality of life domains or analyses were prespecified (<LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>; <LINK REF="REF-ISRCTN76330611" TYPE="REFERENCE">ISRCTN76330611</LINK>). To reduce the risk of selective reporting in the review, we reported summary scores for both scales and both types of analysis, including results for the SAQLI symptoms score, which was a primary quality of life outcome in the trial.</P>
<P>The review authors clarified eligible comparisons in the methods, explicitly excluding trials assessing the timing of initiation and other aspects of NIV delivery or specification. This decision excludes some studies of NIV, limiting its scope to the central question of the effects of NIV versus 'standard care' or versus no NIV as originally intended. New, ongoing studies are addressing further issues about the timing of NIV initiation and further titration with the disease progression. Future reviews will assess different modes, schedules, and initiation of ventilation.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-08-31 14:37:53 +0100" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2017-08-31 14:37:52 +0100" MODIFIED_BY="Ruth Brassington">
<P>Moderate-quality evidence from a single randomised controlled trial (RCT) of non-invasive ventilation (NIV) involving 41 participants suggests that NIV significantly prolongs survival in people with amyotrophic lateral sclerosis (ALS). Low-quality evidence suggests that it maintains quality of life in people with ALS. Survival and some measures of quality of life were significantly improved in the subgroup of people with better bulbar function, but not in those with severe bulbar impairment. Adverse effects related to NIV should be systematically reported, as at present there is little information on this subject.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-08-31 14:37:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>More evidence in the form of RCTs to support the use of NIV in ALS will be difficult to generate, as not offering NIV to the control group is no longer ethically justifiable. Future studies should examine the benefits of early intervention with NIV and establish the most appropriate timing for initiating NIV, in order to obtain its maximum benefit. The effect of adding cough augmentation techniques to NIV also needs to be ascertained in an RCT. Future studies should examine the health economics of NIV and factors influencing access to NIV. Access to NIV remains restricted in many parts of the world, including Europe and North America. We need to understand the factors, personal and socioeconomic, that determine access to NIV.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-10-02 17:29:51 +0100" MODIFIED_BY="Sophie Maprayil">
<P>We thank Dr EA Oppenheimer for his comments on earlier drafts of the protocol. We are grateful to Professor Nigel Leigh, who developed the protocol for this review and contributed to the original assessment of studies, and Kate Jewitt, former Managing Editor of the Cochrane Neuromuscular Disease Group, who was an author of the original review. Angela Gunn, Information Specialist at Cochrane Neuromuscular, performed the searches.</P>
<P>This project was supported by the National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases and the Motor Neuron Disease Association.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-10-02 17:52:10 +0100" MODIFIED_BY="Sophie Maprayil">
<P>Aleksandar Radunovic: Member of the Data and Ethics Monitoring Committee for the NIHR Health Technology Assessment RCT of diaphragm pacing in ALS (DiPALS). Member of the NICE Guideline Development Group on management of MND.</P>
<P>Djillali Annane: no conflicts of interest.</P>
<P>Muhammad K Rafiq: no conflicts of interest.</P>
<P>Ruth Brassington: I have no known financial conflicts of interest. I am Managing Editor of Cochrane Neuromuscular, of which the National Institute for Health Research (NIHR) is the largest single funder. Upon joining the author team, I withdrew from the editorial process for this review, in accordance with Cochrane policy. The Motor Neurone Disease Association also supported Cochrane Neuromuscular with a small grant that contributed to my salary.</P>
<P>Naveed Mustfa: no conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-08-31 14:38:18 +0100" MODIFIED_BY="Ruth Brassington">
<P>Aleksandar Radunovic drafted the first version of the review, with Naveed Mustfa and Djillali Annane. Kate Jewitt edited the protocol and the original version of the review. Muhammad K Rafiq with Djillali Annane selected studies for the first update; the other authors approved the text. Muhammad K Rafiq with Naveed Mustfa assessed studies for the 2017 update of the review, and Ruth Brassington assisted with updating the text and extraction of additional data. All authors approved the final text.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-09-18 14:58:20 +0100" MODIFIED_BY="Sophie Maprayil">
<P>P Nigel Leigh withdrew from authorship after protocol publication. Kate Jewitt withdrew following publication of the full review. Muhammad K Rafiq became an author for the previous update, and Ruth Brassington joined as an author at this update.</P>
<P>The review authors assessed risk of bias expressed as &#8216;low risk&#8217;, &#8216;high risk&#8217;, or &#8216;unclear risk&#8217; of bias in accordance with <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>.</P>
<P>We included a statement in <LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK> that we will include comparisons with no intervention or the best standard care, and clarified that adverse events will be collected from included trials. We reworded the review objective in accordance with current guidance. In addition, we clarified that all forms of NIV irrespective of pressure settings and timings are eligible for inclusion.</P>
<P>We added an appendix describing methods that will be used if meta-analysis becomes possible.</P>
<P>We included a 'Summary of findings' table and searched clinical trials databases, according to current Cochrane requirements.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-10-02 17:53:46 +0100" MODIFIED_BY="Sophie Maprayil">
<STUDIES MODIFIED="2017-09-18 15:34:13 +0100" MODIFIED_BY="Sophie Maprayil">
<INCLUDED_STUDIES MODIFIED="2012-09-13 16:11:50 +0100" MODIFIED_BY="Kate Jewitt">
<STUDY DATA_SOURCE="PUB" ID="STD-Bourke-2006" MODIFIED="2012-09-13 16:11:50 +0100" MODIFIED_BY="Kate Jewitt" NAME="Bourke 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-09-13 16:11:50 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ</AU>
<TI>Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>140-7</PG>
<IDENTIFIERS MODIFIED="2012-05-01 17:32:34 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914423"/><IDENTIFIER MODIFIED="2012-05-01 17:32:34 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="16426990"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914422"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-2001" MODIFIED="2009-05-19 11:38:17 +0100" MODIFIED_BY="Kate Jewitt" NAME="Jackson 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-19 11:38:17 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M, et al</AU>
<TI>A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>75-8</PG>
<IDENTIFIERS MODIFIED="2009-01-27 21:11:05 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914425"/><IDENTIFIER MODIFIED="2009-01-27 21:11:05 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11676995"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-27 21:50:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914424"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-09-18 15:34:13 +0100" MODIFIED_BY="Sophie Maprayil">
<STUDY DATA_SOURCE="PUB" ID="STD-Aboussouan-1997" MODIFIED="2009-05-19 11:38:33 +0100" MODIFIED_BY="Kate Jewitt" NAME="Aboussouan 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-19 11:38:33 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H</AU>
<TI>Effect of non invasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>127</VL>
<NO>6</NO>
<PG>450-3</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:38:23 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914427"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-28 12:06:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914426"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bach-1993" MODIFIED="2009-05-19 11:39:21 +0100" MODIFIED_BY="Kate Jewitt" NAME="Bach 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-05-19 11:39:21 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR</AU>
<TI>Amyotrophic lateral sclerosis. Communication status and survival with ventilatory support</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>6</NO>
<PG>343-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914429"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914428"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlowitz-2016" MODIFIED="2017-08-31 14:45:33 +0100" MODIFIED_BY="Ruth Brassington" NAME="Berlowitz 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-08-31 14:45:33 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlowitz DJ, Howard ME, Fiore JF Jr, Vander Hoorn S, O'Donoghue FJ, Westlake J, et al</AU>
<TI>Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2016</YR>
<VL>87</VL>
<NO>3</NO>
<PG>280-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6819147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6819146"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buhr_x002d_Schinner-1999" MODIFIED="2009-05-19 11:39:06 +0100" MODIFIED_BY="Kate Jewitt" NAME="Buhr-Schinner 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-19 11:39:06 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buhr-Schinner H, Laier-Groeneveld G, Criée CP</AU>
<TI>Amyotrophic lateral sclerosis and nasal mechanical ventilation</TI>
<SO>Medizinische Klinik (Munich)</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>1 Spec No</NO>
<PG>102-4</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:38:41 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914431"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914430"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cazzolli-1996" MODIFIED="2017-08-04 05:27:18 +0100" MODIFIED_BY="[Empty name]" NAME="Cazzolli 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-28 14:58:57 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cazzolli PA, Oppenheimer EA</AU>
<TI>Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1996</YR>
<VL>139</VL>
<NO>Suppl</NO>
<PG>123-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914433"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914432"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cedarbaum-2001" MODIFIED="2013-02-15 14:48:10 +0000" MODIFIED_BY="Kate Jewitt" NAME="Cedarbaum 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-02-15 14:48:10 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cedarbaum JM, Stambler N</AU>
<TI>Disease status and use of ventilatory support by ALS patients. BDNF Study Group</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>1</NO>
<PG>19-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914435"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914434"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-1997" MODIFIED="2009-05-19 11:39:55 +0100" MODIFIED_BY="Kate Jewitt" NAME="David 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-19 11:39:55 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David WS, Bundlie SR, Mahdavi Z</AU>
<TI>Polysomnographic studies in amyotrophic lateral sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>152</VL>
<NO>Suppl 1</NO>
<PG>S29-35</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:39:43 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914437"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914436"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goulon-1989" MODIFIED="2009-01-28 14:55:34 +0000" MODIFIED_BY="Kate Jewitt" NAME="Goulon 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-01-28 14:55:31 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goulon M, Goulon-Goëau C</AU>
<TI>Amyotrophic lateral sclerosis and respiratory support</TI>
<TO>Sclérose latérale amyotrophique et assistance respiratoire</TO>
<SO>Revue Neurologique</SO>
<YR>1989</YR>
<VL>145</VL>
<NO>4</NO>
<PG>293-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914439"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914438"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2016" MODIFIED="2017-08-31 14:45:52 +0100" MODIFIED_BY="Ruth Brassington" NAME="Jacobs 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-08-31 14:45:52 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs TL, Brown DL, Baek J, Migda EM, Funckes T, Gruis KL</AU>
<TI>Trial of early noninvasive ventilation for ALS: a pilot placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2016</YR>
<VL>87</VL>
<NO>18</NO>
<PG>1878-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6819149"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-08-31 14:45:47 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00580593</AU>
<TI>Pilot placebo-controlled trial of early noninvasive ventilation for amyotrophic lateral sclerosis.</TI>
<SO>clinicaltrials.gov/show/NCT00580593</SO>
<YR>(first received 16 July 2007)</YR>
<IDENTIFIERS MODIFIED="2016-12-23 16:26:06 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6819150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6819148"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamimoto-1989" MODIFIED="2009-05-19 11:40:28 +0100" MODIFIED_BY="Kate Jewitt" NAME="Kamimoto 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-05-19 11:40:28 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamimoto K, Murakam N, Muroga T, Matsubara M, Yamamoto M</AU>
<TI>A comparative study between amyotrophic lateral sclerosis patients with and without mechanical ventilation</TI>
<SO>Clinical Neurology</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>8</NO>
<PG>989-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914440"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kleopa-1999" MODIFIED="2009-05-19 11:40:53 +0100" MODIFIED_BY="Kate Jewitt" NAME="Kleopa 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-19 11:40:53 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T</AU>
<TI>Bipap improves survival and rate of pulmonary function decline in patients with ALS</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1999</YR>
<VL>164</VL>
<NO>1</NO>
<PG>82-8</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:40:53 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914443"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914442"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lo-Coco-2006" MODIFIED="2009-08-11 13:49:25 +0100" MODIFIED_BY="[Empty name]" NAME="Lo Coco 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-11 13:49:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lo Coco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Coco A</AU>
<TI>Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>5</NO>
<PG>761-5</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:41:10 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914445"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-29 15:59:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914444"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lo-Coco-2007" MODIFIED="2009-05-19 11:41:25 +0100" MODIFIED_BY="Kate Jewitt" NAME="Lo Coco 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-05-19 11:41:25 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lo Coco D, Marchese S, La Bella V, Piccoli T, Lo Coco A</AU>
<TI>The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>1</NO>
<PG>64-9</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:41:25 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914447"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914446"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyall-2001b" MODIFIED="2013-02-15 14:48:27 +0000" MODIFIED_BY="[Empty name]" NAME="Lyall 2001b" YEAR="2001">
<REFERENCE MODIFIED="2013-02-15 14:48:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, et al</AU>
<TI>A prospective study of quality of life in ALS patients treated with non-invasive ventilation</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>1</NO>
<PG>153-6</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:43:12 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914448"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mustfa-2006" MODIFIED="2016-08-26 16:16:11 +0100" MODIFIED_BY="Ruth Brassington" NAME="Mustfa 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-08-26 16:16:11 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mustfa N, Walsh E, Bryant V, Lyall RA, Addington-Hall J, Goldstein LH, et al</AU>
<TI>The effect of noninvasive ventilation on ALS patients and their caregivers</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>66</VL>
<NO>8</NO>
<PG>1211-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6819152"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6819151"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00386464" MODIFIED="2017-09-18 15:19:03 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT00386464" YEAR="6464">
<REFERENCE MODIFIED="2017-09-18 15:19:03 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00386464</AU>
<TI>Noninvasive ventilation in ALS patients with mild respiratory involvement</TI>
<SO>clinicaltrials.gov/show/NCT00386464</SO>
<YR>(first received 10 October 2006)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914451"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914450"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00537446" MODIFIED="2017-09-18 15:19:10 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT00537446" YEAR="7446">
<REFERENCE MODIFIED="2017-09-18 15:19:10 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00537446</AU>
<TI>Effect of noninvasive ventilation on lung function in amyotrophic lateral sclerosis</TI>
<SO>clinicaltrials.gov/show/NCT00537446</SO>
<YR>(first received 27 September 2007)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914453"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914452"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00560287" MODIFIED="2017-09-18 15:19:16 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT00560287" YEAR="0287">
<REFERENCE MODIFIED="2017-09-18 15:19:16 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00560287</AU>
<TI>Non-invasive ventilation in amyotrophic lateral sclerosis</TI>
<SO>clinicaltrials.gov/show/NCT00560287</SO>
<YR>(first received 16 November 2007)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914455"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914454"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-NCT00958048" MODIFIED="2017-09-18 15:22:18 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT00958048" YEAR="2009">
<REFERENCE MODIFIED="2016-12-21 14:51:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Lee P</AU>
<TI>NIV in ALS [personal communication]</TI>
<SO>Email to: M Rafiq</SO>
<YR>15 June 2015</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914457"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-09-18 15:22:18 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00958048</AU>
<TI>Effects of nocturnal non-invasive ventilation in patients with amyotrophic lateral sclerosis</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00958048</SO>
<YR>(first received 8 February 2009</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914458"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914456"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01363882" MODIFIED="2017-09-18 15:22:23 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT01363882" YEAR="2011">
<REFERENCE MODIFIED="2017-09-18 15:22:23 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01363882</AU>
<TI>Polysomnography-directed noninvasive ventilation in amyotrophic lateral sclerosis (ALS)</TI>
<SO>clinicaltrials.gov/show/NCT01363882</SO>
<YR>(first received 28 March 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914460"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01641965" MODIFIED="2017-09-18 15:22:30 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT01641965" YEAR="2012">
<REFERENCE MODIFIED="2017-09-14 15:07:38 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez N, Prats E, Rodriguez-Gonzalez MJ, Marti S, Lujan M, Povedano MP</AU>
<TI>Effects of early non invasive ventilation on pulmonary function in ALS patients: preliminary results of a randomized controlled trial</TI>
<SO>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6819153"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-09-18 15:22:30 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01641965</AU>
<TI>Impact of early non invasive ventilation in amyotrophic lateral sclerosis (ALS) patients</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01641965</SO>
<YR>(first received 13 July 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914462"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914461"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01746381" MODIFIED="2017-09-18 15:23:45 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT01746381" YEAR="6381">
<REFERENCE MODIFIED="2017-09-18 15:23:45 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01746381</AU>
<TI>Non-invasive ventilation in amyotrophic lateral sclerosis (ALS) using the iVAPS mode</TI>
<SO>clinicaltrials.gov/ct2/show/NCT01746381</SO>
<YR>(first received 4 December 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914464"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914463"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02537132" MODIFIED="2017-09-18 15:34:13 +0100" MODIFIED_BY="Sophie Maprayil" NAME="NCT02537132" YEAR="7132">
<REFERENCE MODIFIED="2017-09-18 15:34:13 +0100" MODIFIED_BY="Sophie Maprayil" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02537132</AU>
<TI>New perspectives of adaptation to NIV in ALS</TI>
<SO>clinicaltrials.gov/show/NCT02537132</SO>
<YR>(first received 28 August 2015)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newsom_x002d_Davis-2001" MODIFIED="2017-08-31 14:46:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Newsom-Davis 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-08-31 14:46:05 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH</AU>
<TI>The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in ALS: a prospective study</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2001</YR>
<VL>71</VL>
<NO>4</NO>
<PG>482-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914468"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914467"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-2003" MODIFIED="2009-05-19 11:42:34 +0100" MODIFIED_BY="Kate Jewitt" NAME="Perez 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-19 11:42:34 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez T, Salachas F</AU>
<TI>Early nasal ventilation in amyotrophic lateral sclerosis: impact on survival and quality of life (the VNP-SLA study)</TI>
<SO>Revue des Maladies Respiratoires</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>4</NO>
<PG>589-98</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914470"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914469"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1995" MODIFIED="2009-05-19 11:43:48 +0100" MODIFIED_BY="Kate Jewitt" NAME="Pinto 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-05-19 11:43:48 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luís ML</AU>
<TI>Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1995</YR>
<VL>129</VL>
<NO>Suppl</NO>
<PG>19-26</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:43:20 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914472"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-27 22:05:44 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914471"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-1999" MODIFIED="2009-08-11 13:52:16 +0100" MODIFIED_BY="[Empty name]" NAME="Pinto 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-08-11 13:52:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto AC, Alves M, Nogueira A, Evangelista T, Carvalho J, Coelho A, et al</AU>
<TI>Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise?</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1999</YR>
<VL>169</VL>
<NO>1-2</NO>
<PG>69-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinto-2003" MODIFIED="2013-02-15 14:48:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Pinto 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-15 14:48:38 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto A, de Carvalho M, Evangelista T, Lopes A, Sales-Luis L</AU>
<TI>Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-1999" MODIFIED="2017-08-31 14:46:19 +0100" MODIFIED_BY="Ruth Brassington" NAME="Saito 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-08-31 14:46:19 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saito T</AU>
<TI>Mechanical ventilation for amyotrophic lateral sclerosis - making a comparison between hospital and home care</TI>
<SO>Rinsho Shinkeigaku (Clinical Neurology)</SO>
<YR>1999</YR>
<VL>39</VL>
<NO>1</NO>
<PG>70-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoesmith-2007" MODIFIED="2017-08-31 14:46:12 +0100" MODIFIED_BY="Ruth Brassington" NAME="Shoesmith 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-08-31 14:46:12 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoesmith CL, Findlater K, Rowe A, Strong MJ</AU>
<TI>Prognosis of amyotrophic lateral sclerosis with respiratory onset</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2007</YR>
<VL>78</VL>
<NO>6</NO>
<PG>629-31</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:44:59 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914480"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sivak-1982" MODIFIED="2009-05-19 11:45:29 +0100" MODIFIED_BY="Kate Jewitt" NAME="Sivak 1982" YEAR="1982">
<REFERENCE MODIFIED="2009-05-19 11:45:29 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivak ED, Gipson WT, Hanson MR</AU>
<TI>Long-term management of respiratory failure in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1982</YR>
<VL>12</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914482"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winterholler-2001" MODIFIED="2009-05-19 11:45:44 +0100" MODIFIED_BY="Kate Jewitt" NAME="Winterholler 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-19 11:45:44 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winterholler MG, Erbguth FJ, Hecht MJ, Heuss D, Neundörfer B</AU>
<TI>Survival with artificial respiration at home. An open, prospective study on home ventilation for neuromuscular diseases, in particular, the situation of ALS patients</TI>
<SO>Nervenarzt</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>4</NO>
<PG>293-301</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:45:44 +0100" MODIFIED_BY="Kate Jewitt"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2914484"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2914483"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-12-11 12:19:43 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2016-12-21 16:32:08 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-09-14 15:10:05 +0100" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2017-09-14 15:10:05 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Aboussouan-2001" MODIFIED="2009-05-19 11:46:11 +0100" MODIFIED_BY="Kate Jewitt" NAME="Aboussouan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Aboussouan LS, Khan SU, Banerjee M, Arroligan AC, Mitsumoto H</AU>
<TI>Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>3</NO>
<PG>403-9</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:46:11 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-ALSFRS-1996" MODIFIED="2017-08-31 14:46:29 +0100" MODIFIED_BY="Ruth Brassington" NAME="ALSFRS 1996" TYPE="JOURNAL_ARTICLE">
<AU>The ALS CNTF (ACTS) Phase I-II Study Group</AU>
<TI>The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>2</NO>
<PG>141-7</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:46:16 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Annane-2014" MODIFIED="2015-08-28 10:32:14 +0100" MODIFIED_BY="[Empty name]" NAME="Annane 2014" TYPE="COCHRANE_REVIEW">
<AU>Annane D, Orlikowski D, Chevret S</AU>
<TI>Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-08-21 16:16:34 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2015-08-21 16:16:34 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001941.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bach-1995" MODIFIED="2009-05-19 11:46:27 +0100" MODIFIED_BY="Kate Jewitt" NAME="Bach 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR</AU>
<TI>Amyotrophic lateral sclerosis: predictors for prolongation of life by noninvasive respiratory aids</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>9</NO>
<PG>828-32</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:46:27 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Bach-2002" MODIFIED="2017-08-31 14:57:39 +0100" MODIFIED_BY="Ruth Brassington" NAME="Bach 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bach JR</AU>
<TI>Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory aids</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>1</NO>
<PG>92-8</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:46:38 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Baxter-2013a" MODIFIED="2017-08-31 14:46:46 +0100" MODIFIED_BY="Ruth Brassington" NAME="Baxter 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Baxter SK, Baird WO, Thompson S, Bianchi SM, Walters SJ, Lee E, et al</AU>
<TI>The initiation of non-invasive ventilation for patients with motor neuron disease: patient and carer perceptions of obstacles and outcomes</TI>
<SO>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>2</NO>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baxter-2013b" MODIFIED="2015-09-05 12:25:59 +0100" MODIFIED_BY="[Empty name]" NAME="Baxter 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Baxter SK, Baird WO, Thompson S, Bianchi SM, Walters SJ, Lee E, et al</AU>
<TI>The use of non-invasive ventilation at end of life in patients with motor neurone disease: a qualitative exploration of family carer and health professional experiences</TI>
<SO>Palliative Medicine</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>6</NO>
<PG>516-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baxter-2013c" MODIFIED="2015-12-10 21:59:04 +0000" MODIFIED_BY="Ruth Brassington" NAME="Baxter 2013c" TYPE="JOURNAL_ARTICLE">
<AU>Baxter SK, Baird WO, Thompson S, Bianchi SM, Walters SJ, Lee E, et al</AU>
<TI>The impact on the family carer of motor neurone disease and intervention with noninvasive ventilation</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2013</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1602-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borasio-1998" MODIFIED="2017-08-31 14:46:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Borasio 1998" TYPE="JOURNAL_ARTICLE">
<AU>Borasio GD, Gelinas DF, Yanagisawa N</AU>
<TI>Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective</TI>
<SO>Journal of Neurology</SO>
<YR>1998</YR>
<VL>245</VL>
<NO>Suppl 2</NO>
<PG>S7-12</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:46:46 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Borasio-2001" MODIFIED="2015-12-10 21:59:39 +0000" MODIFIED_BY="Ruth Brassington" NAME="Borasio 2001" TYPE="JOURNAL_ARTICLE">
<AU>Borasio GD, Shaw PJ, Hardiman, Ludolph AC, Sales Luis M, Silani V</AU>
<TI>Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>3</NO>
<PG>159-64</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:47:15 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Bourke-2001" MODIFIED="2013-02-15 15:14:12 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bourke 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bourke SC, Shaw PJ, Gibson GJ</AU>
<TI>Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>11</NO>
<PG>2040-4</PG>
<IDENTIFIERS MODIFIED="2012-07-22 12:51:21 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Bourke-2002" MODIFIED="2015-12-10 22:00:28 +0000" MODIFIED_BY="Ruth Brassington" NAME="Bourke 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bourke SC, Williams TL, Bullock RE, Gibson GJ, Shaw PJ</AU>
<TI>Non-invasive ventilation in motor neuron disease: current UK practice</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>3</NO>
<PG>145-9</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:47:30 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Bradley-2001" MODIFIED="2009-08-11 13:52:41 +0100" MODIFIED_BY="[Empty name]" NAME="Bradley 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bradley WG, Anderson F, Bromberg M, Gutmann C, Harati Y, Ross M, et al</AU>
<TI>Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>3</NO>
<PG>500-4</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:47:36 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-1994" MODIFIED="2009-05-19 11:47:43 +0100" MODIFIED_BY="Kate Jewitt" NAME="Brooks 1994" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR</AU>
<TI>El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>Suppl</NO>
<PG>96-107</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:47:43 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2000" MODIFIED="2015-12-10 22:01:03 +0000" MODIFIED_BY="Ruth Brassington" NAME="Brooks 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases</AU>
<TI>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>5</NO>
<PG>293-9</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:47:52 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Carratu-2009" MODIFIED="2013-02-15 14:49:37 +0000" MODIFIED_BY="[Empty name]" NAME="Carratu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Carratù P, Spicuzza L, Cassano A, Maniscalco M, Gadaleta F, Lacedonia D, et al</AU>
<TI>Early treatment with noninvasive positive pressure ventilation prolongs survival in amyotrophic lateral sclerosis patients with nocturnal respiratory insufficiency</TI>
<SO>Orphanet Journal of Rare Diseases</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-01-25 14:53:53 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2013-01-25 14:53:53 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1186/1750-1172-4-10"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cedarbaum-1999" MODIFIED="2009-08-10 00:18:09 +0100" MODIFIED_BY="Ruth Brassington" NAME="Cedarbaum 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond E, et al</AU>
<TI>The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1999</YR>
<VL>169</VL>
<NO>1-2</NO>
<PG>13-21</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:48:00 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Chaudri-2000" MODIFIED="2009-05-19 11:48:15 +0100" MODIFIED_BY="Kate Jewitt" NAME="Chaudri 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chaudri MB, Liu C, Watson L, Jefferson D, Kinnear WJ</AU>
<TI>Sniff nasal pressure as a marker of respiratory function in motor neuron disease</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>3</NO>
<PG>539-42</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:48:15 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Chio-2001" MODIFIED="2009-05-19 11:48:23 +0100" MODIFIED_BY="Kate Jewitt" NAME="Chio 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chio A, Silani V; Italian ALS Study Group</AU>
<TI>Amyotrophic lateral sclerosis in Italy: a nationwide study in neurological centers</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>145-50</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:48:23 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Fitting-1999" MODIFIED="2009-05-19 11:48:30 +0100" MODIFIED_BY="Kate Jewitt" NAME="Fitting 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fitting JW, Paillex R, Hirt L, Aebischer P, Schluep M</AU>
<TI>Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>6</NO>
<PG>887-93</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:48:30 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Haverkamp-1995" MODIFIED="2017-08-04 06:04:55 +0100" MODIFIED_BY="[Empty name]" NAME="Haverkamp 1995" TYPE="JOURNAL_ARTICLE">
<AU>Haverkamp LJ, Appel V, Appel SH</AU>
<TI>Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model of survival prediction</TI>
<SO>Brain</SO>
<YR>1995</YR>
<VL>118</VL>
<NO>Pt 3</NO>
<PG>707-19</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:48:36 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Hayashi-1997" MODIFIED="2017-08-31 14:47:18 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hayashi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi H</AU>
<TI>Ventilatory support: Japanese experience</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>152</VL>
<NO>Suppl 1</NO>
<PG>S97-100</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:48:46 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Hein-1997" MODIFIED="2015-12-10 22:01:24 +0000" MODIFIED_BY="Ruth Brassington" NAME="Hein 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hein H, Schucher B, Kirsten D, Magnussen H</AU>
<TI>Prospective study of the quality of life in intermittent self-ventilation</TI>
<SO>Medizinische Klinik</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>Suppl 1</NO>
<PG>93-4</PG>
<IDENTIFIERS MODIFIED="2015-12-10 22:01:24 +0000" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Hein-1999" MODIFIED="2017-08-31 14:47:44 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hein 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hein H, Schucher B, Magnussen H</AU>
<TI>Intermittent assisted ventilation in neuromuscular diseases: course and quality of life</TI>
<SO>Pneumonologie</SO>
<YR>1999</YR>
<VL>53 Suppl 2</VL>
<PG>S89-90</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="20079874"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-08-31 14:47:32 +0100" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<PB>

</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISRCTN76330611" MODIFIED="2017-08-31 14:47:50 +0100" MODIFIED_BY="Ruth Brassington" NAME="ISRCTN76330611" TYPE="OTHER">
<AU>ISRCTN76330611</AU>
<TI>Sleep disordered breathing and the impact of nocturnal non-invasive ventilatory support on quality of life in motor neurone disease</TI>
<SO>www.isrctn.com/ISRCTN76330611</SO>
<YR>(accesssed 23 June 2016)</YR>
<IDENTIFIERS MODIFIED="2016-06-23 16:56:25 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-06-23 16:56:25 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1186/ISRCTN76330611"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jones-2012" MODIFIED="2017-08-31 14:47:56 +0100" MODIFIED_BY="Ruth Brassington" NAME="Jones 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jones U, Enright S, Busse M</AU>
<TI>Management of respiratory problems in people with neurodegenerative conditions: a narrative review</TI>
<SO>Physiotherapy</SO>
<YR>2012</YR>
<VL>98</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kawata-2008" MODIFIED="2013-02-15 14:50:17 +0000" MODIFIED_BY="[Empty name]" NAME="Kawata 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kawata A, Mizoguchi K, Hayashi H</AU>
<TI>A nationwide survey of ALS patients on tracheostomy positive pressure ventilation (TPPV) who developed a totally locked-in state (TLS) in Japan</TI>
<SO>Rinsho Shinkeigaku</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>7</NO>
<PG>476-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lechtzin-2002" MODIFIED="2009-05-19 11:49:17 +0100" MODIFIED_BY="Kate Jewitt" NAME="Lechtzin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lechtzin N, Wiener CM, Shade DM, Clawson L, Diette GB</AU>
<TI>Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>121</VL>
<NO>2</NO>
<PG>436-42</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:49:17 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Lyall-2001a" MODIFIED="2013-01-25 11:23:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lyall 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J</AU>
<TI>Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis</TI>
<SO>Brain</SO>
<YR>2001</YR>
<VL>124</VL>
<NO>Pt 10</NO>
<PG>2000-13</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:49:27 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Mehta-2001" MODIFIED="2013-02-15 14:50:27 +0000" MODIFIED_BY="[Empty name]" NAME="Mehta 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mehta S, Hill NS</AU>
<TI>Noninvasive ventilation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>2</NO>
<PG>540-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melo-1999" MODIFIED="2009-08-10 00:18:54 +0100" MODIFIED_BY="Ruth Brassington" NAME="Melo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Melo J, Homma A, Iturriaga E, Frierson L, Amato A, Anzueto A, et al</AU>
<TI>Pulmonary evaluation and prevalence of non-invasive ventilation in patients with amyotrophic lateral sclerosis: a multicenter survey and proposal of a pulmonary protocol</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1999</YR>
<VL>169</VL>
<NO>1-2</NO>
<PG>114-7</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:49:33 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2012" MODIFIED="2016-12-21 14:52:40 +0000" MODIFIED_BY="[Empty name]" NAME="Miller 2012" TYPE="COCHRANE_REVIEW">
<AU>Miller RG, Mitchell JD, Moore DH</AU>
<TI>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-12-02 23:18:24 +0000" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2015-12-02 23:18:24 +0000" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001447.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moss-1993" MODIFIED="2009-05-19 11:50:13 +0100" MODIFIED_BY="Kate Jewitt" NAME="Moss 1993" TYPE="JOURNAL_ARTICLE">
<AU>Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M</AU>
<TI>Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>2</NO>
<PG>438-43</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:50:13 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Moss-1996" MODIFIED="2017-08-31 14:48:47 +0100" MODIFIED_BY="Ruth Brassington" NAME="Moss 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moss AH, Oppenheimer EA, Casey P, Cazzolli PA, Roose RP, Stocking CB, et al</AU>
<TI>Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation: advance care planning and outcomes</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>1</NO>
<PG>249-55</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:50:23 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2017-08-31 14:48:13 +0100" MODIFIED_BY="Ruth Brassington" NAME="NICE 2010" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Motor neurone disease: non-invasive ventilation</TI>
<SO>London: National Institute for Health and Care Excellence; July 2010. Clinical guideline [CG105]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-1974" MODIFIED="2017-08-31 14:48:42 +0100" MODIFIED_BY="Ruth Brassington" NAME="Norris 1974" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH, Calanchini PR, Fallat R, Panchari S, Jewett BJ</AU>
<TI>The administration of guanidine in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1974</YR>
<VL>24</VL>
<NO>8</NO>
<PG>721-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Neill-2012" MODIFIED="2017-08-31 14:48:36 +0100" MODIFIED_BY="Ruth Brassington" NAME="O'Neill 2012" TYPE="JOURNAL_ARTICLE">
<AU>O'Neill CL, Williams TL, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, et al</AU>
<TI>Non-invasive ventilation in motor neuron disease: an update of current UK practice</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2012</YR>
<VL>83</VL>
<NO>4</NO>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2009-05-19 11:51:08 +0100" MODIFIED_BY="Kate Jewitt" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:50:33 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-12-10 22:02:25 +0000" MODIFIED_BY="Ruth Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stambler-1998" MODIFIED="2009-05-19 11:50:40 +0100" MODIFIED_BY="Kate Jewitt" NAME="Stambler 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stambler N, Charatan M, Cedarbaum JM</AU>
<TI>Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>1</NO>
<PG>66-72</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:50:40 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2017-09-14 15:10:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2003" MODIFIED="2017-08-31 14:48:55 +0100" MODIFIED_BY="Ruth Brassington" NAME="Turner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A</AU>
<TI>Prolonged survival in motor neuron disease: a descriptive study of the King's Database 1990-2000</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>7</NO>
<PG>995-7</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:50:47 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Varrato-2001" MODIFIED="2009-05-19 11:50:54 +0100" MODIFIED_BY="Kate Jewitt" NAME="Varrato 2001" TYPE="JOURNAL_ARTICLE">
<AU>Varrato J, Siderwof A, Damiano P, Gregory S, Feinberg D, McCluskey L</AU>
<TI>Postural change of forced vital capacity predicts some respiratory symptoms in ALS</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>2</NO>
<PG>357-9</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:50:54 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Vitacca-1997" MODIFIED="2009-08-10 00:19:30 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vitacca 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vitacca M, Clini E, Facchetti D, Pagani M, Polani M, Porta R, et al</AU>
<TI>Breathing pattern and respiratory mechanics in patients with amyotrophic lateral sclerosis</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>7</NO>
<PG>1614-21</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:51:42 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Worms-2001" MODIFIED="2009-05-19 11:51:57 +0100" MODIFIED_BY="Kate Jewitt" NAME="Worms 2001" TYPE="JOURNAL_ARTICLE">
<AU>Worms PM</AU>
<TI>The epidemiology of motor neuron diseases: a review of recent studies</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>3-9</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:51:57 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Yamaguchi-2001" MODIFIED="2017-08-31 14:48:30 +0100" MODIFIED_BY="Ruth Brassington" NAME="Yamaguchi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yamaguchi M, Hideaki H, Kuniko H</AU>
<TI>Ventilatory support in Japan: a new life with ALS and a positive approach to living with the disease</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>4</NO>
<PG>209-11</PG>
<IDENTIFIERS MODIFIED="2009-05-19 11:52:05 +0100" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-08-31 14:49:30 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Leigh-2003" MODIFIED="2017-08-31 14:49:23 +0100" MODIFIED_BY="Ruth Brassington" NAME="Leigh 2003" TYPE="COCHRANE_PROTOCOL">
<AU>Leigh PN, Annane D, Jewitt K, Mustfa N</AU>
<TI>Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-01-25 15:11:12 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2013-01-25 15:11:12 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD004427"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Radunovic-2009" MODIFIED="2012-09-14 15:27:16 +0100" MODIFIED_BY="Ruth Brassington" NAME="Radunovic 2009" TYPE="COCHRANE_REVIEW">
<AU>Radunovic A, Annane D, Jewitt K, Mustfa N</AU>
<TI>Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-08-24 13:12:51 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2012-08-24 13:12:51 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD004427.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Radunovic-2013" MODIFIED="2017-08-31 14:49:30 +0100" MODIFIED_BY="Ruth Brassington" NAME="Radunovic 2013" TYPE="COCHRANE_REVIEW">
<AU>Radunovic A, Annane D, Rafiq MK, Mustfa N</AU>
<TI>Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-06-03 12:27:29 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2015-06-03 12:27:29 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD004427.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-09-18 14:59:58 +0100" MODIFIED_BY="Sophie Maprayil">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-09-18 14:59:58 +0100" MODIFIED_BY="Sophie Maprayil" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Conflicts of interest for primary investigators" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-08-31 14:56:51 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Bourke-2006">
<CHAR_METHODS MODIFIED="2009-01-26 22:47:49 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-31 14:56:49 +0100" MODIFIED_BY="Ruth Brassington">
<P>41 participants with ALS</P>
<P>Age: 63.7 ± 10.3 and 63.0 ± 8.1 years</P>
<P>Male sex 64% and 53%</P>
<P>Disease duration 1.9 ± 1.3 and 2.0 ± 1.1 years</P>
<P>Baseline characteristics: vital capacity (% predicted) 55.6 ± 18.7% and 48.8 ± 20.7%, maximum inspiratory pressure - P<SUB>i</SUB>max (% predicted) 31.1 ± 11.0% and 31.0 ± 10.6%, SNIP (% predicted) 22.6 ± 11.4% and 24.4 ± 10.8%, PaCO<SUB>2 </SUB>(mmHg) 6.1 ± 1.1 and 6.4 ± 1.2 in NIV and standard care group respectively at randomisation (mean ± SD)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-08-26 18:30:39 +0100" MODIFIED_BY="Ruth Brassington">
<P>Intervention: NIV (n = 22)</P>
<P>Control: standard care (n = 19)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-31 14:56:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: overall survival after initiation of assisted ventilation</P>
<P>Secondary outcomes: survival at 1 and 6 months, SF-36, and SAQLI</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-08-28 10:21:20 +0100" MODIFIED_BY="[Empty name]">
<P>ResMed UK Ltd and the Motor Neurone Disease Association provided funding for the study.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2017-08-31 14:56:51 +0100" MODIFIED_BY="Ruth Brassington">
<P>No reported conflicts of interest</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-08-26 18:30:43 +0100" MODIFIED_BY="Ruth Brassington">
<P>Protocol: ISRCTN76330611</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-09-18 14:59:58 +0100" MODIFIED_BY="Sophie Maprayil" STUDY_ID="STD-Jackson-2001">
<CHAR_METHODS MODIFIED="2009-01-27 21:15:03 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-08-31 14:56:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>7 participants with ALS in early NIPPV group and 6 participants in late NIPPV group</P>
<P>No age or sex provided.</P>
<P>Baseline characteristics: FVC = 77 ± 13% (mean ± SD) in early NIPPV group at baseline and time of randomisation. FVC = 77 ± 6% (mean ± SD) in late NIPPV at baseline. The time to randomisation (FVC &lt; 50% predicted) for the late NIPPV group = 59 ± 38 days (mean ± SD).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-09-18 14:59:58 +0100" MODIFIED_BY="Sophie Maprayil">
<P>Early NIPPV (FVC 70% to 100%) and late ("standard of care") NIPPV (FVC &lt; 50%) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-08-31 14:56:55 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: not available</P>
<P>Secondary outcomes: survival at 3 months, SF-36, ALSFRS-R, and SAQLI</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-26 18:31:24 +0100" MODIFIED_BY="Ruth Brassington">
<P>National Amyotrophic Lateral Sclerosis Association. Respironics for provision of equipment</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2015-08-28 10:22:24 +0100" MODIFIED_BY="[Empty name]">
<P>No conflicts of interest statement given in the manuscript.</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2017-08-31 14:56:56 +0100" MODIFIED_BY="Ruth Brassington">
<P>Pilot study that failed to develop further, due to lack of funding. The study was deemed as at high risk of bias due to selective reporting.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALS: amyotrophic lateral sclerosis<BR/>ALSFRS-R: revised Amyotrophic Lateral Sclerosis Functional Rating Scale<BR/>FVC: forced vital capacity<BR/>NIPPV: non-invasive positive pressure ventilation<BR/>NIV: non-invasive ventilation<BR/>PaCO<SUB>2: </SUB>partial pressure of carbon dioxide in arterial blood<BR/>SAQLI: Sleep Apnea Quality of Life Index<BR/>SD: standard deviation<BR/>SF-36: 36-Item Short Form Health Survey<BR/>SNIP: sniff nasal inspiratory pressure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-08-31 14:57:12 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:39:33 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Aboussouan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:39:33 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Observational cohort study of 18 NIV tolerant and 21 NIV non-tolerant participants with ALS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:39:35 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Bach-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:39:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study of 89 people with ALS. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:39:37 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Berlowitz-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:39:37 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Study of the effect of NIV on survival and pulmonary function decline across MND/ALS phenotypes using data from 929 people with ALS/MND</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:56:58 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Buhr_x002d_Schinner-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:56:58 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study without control group. 38 people with ALS received intermittent nasal mechanical ventilation using pressure- and volume-cycled respirators.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:56:59 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Cazzolli-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:56:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study. 29 people with ALS used nasal intermittent positive pressure ventilation, and 50 used tracheostomy intermittent positive pressure ventilation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:39:47 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Cedarbaum-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:39:47 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. No control group. 28 participants received BPAP, and 7 received mechanical ventilation via tracheostomy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-15 14:47:43 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-David-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-15 14:47:43 +0000" MODIFIED_BY="Kate Jewitt">
<P>Not a randomised trial. Retrospective study without control group. 13 people with ALS received BPAP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:56:59 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Goulon-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:56:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study of 16 people with ALS receiving assisted ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:01 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Jacobs-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary aim was early initiation of NIV. Once current standard criteria for NIV initiation were reached, both arms were offered NIV. Study did not assess NIV use in people with ALS with respiratory muscle weakness causing ventilator failure or nocturnal hypoventilation with sleep-disordered breathing.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kamimoto-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study of 13 people with ALS receiving mechanical ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:00 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kleopa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study of 122 people with ALS. 38 participants used BPAP for more than 4 hours day, 32 participants used BPAP for less than 4 hours a day, and 52 participants refused to try BPAP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:07 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lo-Coco-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Prospective study of 44 NIV tolerant ALS participants and 27 NIV non-tolerant participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:12 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lo-Coco-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective study of 33 consecutive ALS patients in acute respiratory failure receiving tracheostomy intermittent positive pressure ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:01 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Lyall-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Prospective cohort study of 16 people with ALS on NIV and 11 normal age-matched controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:01 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Mustfa-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. A prospective 1-year study of the efficacy of NIV for ALS. Comparison group declined NIV. Not blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-06 13:48:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00386464">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-06 13:48:17 +0100" MODIFIED_BY="[Empty name]">
<P>Described in trial registry as a randomised comparison of NIV at night or usual care. Investigator responded to review authors' enquiry in November 2015 that the trial had recruitment problems, was not completed, and there have been no publications.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT00537446">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Does not compare ventilation to no ventilation or standard care; compared high-level ventilation versus low-level ventilation (each for 2 hours)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:19 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT00560287">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:19 +0100" MODIFIED_BY="Ruth Brassington">
<P>Does not compare ventilation to no ventilation or standard care; this was a comparison of pressure support versus volume-assisted mode NIV delivered by home care providers. No publication identified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:28 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT00958048">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>Listed in trial registry as a randomised controlled trial of non-invasive ventilation (BPAP) versus no non-invasive ventilation. The contact person (Dr Lee) informed the review authors that the study was converted into an observational study, as participants were not willing to be randomised, hence the study was not eligible for inclusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT01363882">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised trial. Does not compare ventilation to no ventilation or standard care. Polysomnography-guided adjustment of NIV versus standard initiation of NIV</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT01641965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised trial. Does not compare ventilation to no ventilation or standard care; compared home pressure ventilator model Vivo 40 (BREAS Medical AB) initiated early (when FVC is less than 75% predicted) versus standard initiation (when FVC is less than 50% predicted). No outcome data on NIV, survival, or quality of life available in abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:33 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT01746381">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:33 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised trial. Does not compare ventilation to no ventilation or standard care; compared different modes of ventilation (intelligent Volume-Assured Pressure Support (iVAPS) versus standard built-in self test (BiST) mode)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:35 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT02537132">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised trial. Assessment of adaptation to NIV via home- or clinic-based training</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:38 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Newsom_x002d_Davis-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Prospective study of 9 people with ALS with hypoventilation given NIPPV, compared with 10 normal age-matched controls without ventilation problems</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:40 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Perez-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:40 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomised trial terminated early due to problems recruiting participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:10 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Pinto-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Prospective controlled study of 20 consecutive patients, first 10 received standard care and following 10 received NIV</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:57:12 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Pinto-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:57:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Controlled study of exercise in people with ALS with respiratory insufficiency. 8 participants on NIV and 12 ALS controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:47 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Pinto-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:47 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Historical controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:50 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Saito-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective review of 25 cases using positive pressure ventilation with tracheostomy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:52 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Shoesmith-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:52 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Retrospective review of 13 cases</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-08-31 14:40:54 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Sivak-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-08-31 14:40:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial. Anecdotal study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-15 14:47:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winterholler-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-15 14:47:56 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial. Retrospective study without control group. 20 ALS participants received NIPPV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ALS: amyotrophic lateral sclerosis<BR/>BPAP: bilevel positive airway pressure<BR/>MND: motor neuron disease<BR/>NIPPV: non-invasive positive pressure ventilation<BR/>NIV: non-invasive ventilation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-12-11 12:19:43 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-08-31 14:41:06 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-08-31 14:56:57 +0100" MODIFIED_BY="Ruth Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-08-31 14:56:56 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 22:55:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-31 14:56:56 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Described as randomised but no method of randomisation stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-08-31 14:39:09 +0100" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 22:39:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>Immediate allocation following randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-31 14:39:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>2 sets of random assignments in blocks of 4 for each centre were prepared by a statistician. Randomisation was carried out separately for bulbar- and limb-onset participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-08-26 18:22:57 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-08-31 14:56:51 +0100" MODIFIED_BY="Ruth Brassington" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-08-31 14:56:51 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>Not possible to blind delivery of the non-invasive ventilation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-08-28 10:22:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Participants were not blinded to their treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-08-31 14:56:57 +0100" MODIFIED_BY="Ruth Brassington" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-08-31 14:56:52 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>No information given on whether outcome assessors were blinded to knowledge of allocation intervention when assessing the data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-08-31 14:56:57 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Trial described as a single-blind study, with pulmonary assessments, ALSFRS-R, SAQLI, and SF-36 repeated every 3 months by a blinded clinical evaluator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-08-31 14:56:53 +0100" MODIFIED_BY="Ruth Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-31 14:56:53 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>13 withdrawals during surveillance, but no participants withdrew after randomisation. 1 participant alive 45 months after randomisation; all others were followed up to death.</P>
<P>All outcome measures were measured by intention to treat.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-15 14:11:46 +0100" MODIFIED_BY="Ruth  Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Only early NIPPV group analysed, outcome of 1 participant not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-08-31 14:38:55 +0100" MODIFIED_BY="Ruth Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-31 14:38:55 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>The study protocol is available, and all of the study&#8217;s prespecified (primary and secondary) outcomes that are of interest in the review were reported. The report and protocol do not state whether the choice of primary quality of life outcomes in the trial report or the choice of analyses were prespecified, but data were provided for all domains.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-26 18:31:37 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Study protocol not available. Numerical data not systematically reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-08-31 14:39:17 +0100" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-04 15:50:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourke-2006">
<DESCRIPTION>
<P>No other bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-31 14:39:17 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Jackson-2001">
<DESCRIPTION>
<P>Nocturnal hypoventilation not defined as per the universally accepted criteria.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-09-18 15:01:40 +0100" MODIFIED_BY="Sophie Maprayil">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-09-18 15:01:40 +0100" MODIFIED_BY="Sophie Maprayil" NO="1">
<TITLE MODIFIED="2017-08-31 14:41:28 +0100" MODIFIED_BY="Ruth Brassington">Non-invasive ventilation compared with standard care for amyotrophic lateral sclerosis (ALS)</TITLE>
<TABLE COLS="7" ROWS="20">
<TR>
<TD COLSPAN="7">
<P>
<B>Non-invasive ventilation compared with standard care for amyotrophic lateral sclerosis (ALS)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people with ALS</P>
<P>
<B>Settings: </B>people with ALS attending a single regional care centre</P>
<P>
<B>Intervention: </B>non-invasive ventilation</P>
<P>
<B>Comparison: </B>standard care</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Non-invasive ventilation (NIV)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Survival</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median survival was 171 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median survival was 48 days longer (12 to 91 days<SUP>1</SUP> longer).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>41 (1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P/>
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>Moderate<SUP>2</SUP>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>21 of the 41 participants had poor bulbar function.</P>
<P/>
<P>P = 0.0059 better bulbar function, P = 0.92 poor bulbar function</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with better (good or moderately impaired) bulbar function </B>
</P>
<P>Median survival was 11 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with better (good or moderately impaired) bulbar function </B>
</P>
<P>Median survival was 205 days longer (CI not given).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median survival was 261 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median survival was 39 days shorter (CI not given).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Quality of life </B>(SF-36 MCS)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median duration that SF-36 MCS remained above 75% of baseline was 99 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median duration that SF-36 MCS remained above 75% of baseline was 69 days longer (45 to 667 days longer).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>41 (1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>Low<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
-
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with better (good or moderately impaired) bulbar function </B>
</P>
<P>Median duration that SF-36 MCS remained above 75% of baseline was 4 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with better (good or moderately impaired) bulbar function </B>
</P>
<P>Median duration that SF-36 MCS remained above 75% of the baseline was 195 days longer (P = 0.001, CI not given).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median duration that SF-36 MCS remained above 75% of baseline was 164 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median duration that SF-36 MCS remained above 75% of the baseline was 37 days shorter (P = 0.64, CI not given).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Quality of life </B>(SF-36 PCS)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median duration that SF-36 PCS remained above 75% of baseline was 81 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median duration that SF-36 PCS remained above 75% of baseline was 69 days longer (P = 0.004).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>CI not given</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with better (good or moderately impaired) bulbar function </B>
</P>
<P>Median duration that SF-36 PCS remained above 75% of baseline was 4 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with better (good or moderately impaired) bulbar function </B>
</P>
<P>Median duration that SF-36 PCS remained above 75% of the baseline was 175 days longer (P &lt; 0.001).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median duration that SF-36 PCS remained above 75% of baseline was 132 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median duration that SF-36 PCS remained above 75% of the baseline was 18 days longer (P = 0.88).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Quality of life </B>(SAQLI)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median duration that SAQLI remained above 75% of baseline was 99 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All participants</B>
</P>
<P>Median duration that SAQLI remained above 75% of baseline was 74 days longer (P = 0.031).</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>41 (1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>Low<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>CI not given</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with good or moderately impaired bulbar function</B>
</P>
<P>Median duration that SAQLI remained above 75% of baseline was 4 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with good or moderately impaired bulbar function</B>
</P>
<P>Median duration that SAQLI remained above 75% of the baseline was 195 days longer (P = &lt; 0.001).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median duration that SAQLI remained above 75% of baseline was 132 days.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Participants with poor bulbar function</B>
</P>
<P>Median duration that SAQLI remained above 75% of the baseline was 29 days shorter (P = 0.77).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse events</B> (not reported)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
-
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>SAQLI:</B> Sleep Apnea Quality of Life Index; <B>SF-36 MCS:</B> 36-Item Short-Form Health Survey Mental Component Summary; <B>SF-36 PCS:</B> 36-Item Short-Form Health Survey Physical Component Summary</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Calculated CIs are approximate.<BR/>
<SUP>2</SUP>We assessed the evidence as of moderate quality, as it was based on a single randomised trial of 41 participants.<BR/>
<SUP>3</SUP>For quality of life outcomes, we further downgraded the evidence due to lack of blinding.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-09-18 15:11:25 +0100" MODIFIED_BY="Sophie Maprayil">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-09-18 15:06:22 +0100" MODIFIED_BY="Sophie Maprayil" NO="1">
<TITLE MODIFIED="2017-01-31 19:30:21 +0000" MODIFIED_BY="Ruth Brassington">Duration that quality of life was maintained above 75% of baseline (median days)</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>
<B>All participants (n = 41)</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>
<B>Better bulbar function (n = 20)</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>
<B>Poor bulbar function (n = 21)</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NIV (n = 22)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care<BR/>(n = 19)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NIV<BR/>(n = 11)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care<BR/>(n = 9)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NIV (n = 11)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care<BR/>(n = 10)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SF-36 MCS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>168 (45 to 1357)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>99 (0 to 690)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0017</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>199 (48 to 552)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (0 to 196)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>127 (45 to 1357)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>164 (2 to 690)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.64</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SF-36 PCS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>150 (27 to 908)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>81 (0 to 273)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0014</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>179 (36 to 548)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (0 to 94)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>150 (27 to 908)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>132 (2 to 273)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SAQLI symptoms</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>192 (48 to 1357)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46 (0 to 703)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>205 (69 to 629)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (0 to 143)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>143 (48 to 1357)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100 (2 to 703)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.26</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SAQLI score</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>173 (25 to 1357)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>99 (0 to 645)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.031</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>199 (61 to 595)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 (0 to 193)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>103 (25 to 1357)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>132 (2 to 645)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.77</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Data are median (range). Data from <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>.</P>
<P>Abbreviations: NIV: non-invasive ventilation; SAQLI: Sleep Apnea Quality of Life Index; SF-36 MCS: 36-Item Short-Form Health Survey Mental Component Summary; SF-36 PCS: 36-Item Short-Form Health Survey Physical Component Summary</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-09-18 15:11:25 +0100" MODIFIED_BY="Sophie Maprayil" NO="2">
<TITLE MODIFIED="2017-08-31 14:45:05 +0100" MODIFIED_BY="Ruth Brassington">Time-weighted mean improvement in quality of life domains</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>
<B>All participants (n = 41)</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>
<B>Better bulbar function (n = 20)</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="3" VALIGN="BOTTOM">
<P>
<B>Poor bulbar function (n = 21)</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NIV<BR/>(n = 22)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care (n = 19)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NIV (n = 11)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care (n = 9)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>NIV<BR/>(n = 11)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Standard care (n = 10)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SF-36 MCS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.31 (0 to 11.54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 5.23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0082</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2.18 (0 to 11.54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 1.39)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0052</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4.47 (0 to 7.75)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.88 (0 to 5.23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.24</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SF-36 PCS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.18 (0 to 10.62)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 6.73)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.14 (0 to 10.62)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 0.39)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.031</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.21 (0 to 5.41)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.48 (0 to 6.73)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.37</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SAQLI symptoms</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.07 (0 to 3.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1.73 (0.52 to 2.95)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.90 (0 to 3.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.04 (0 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.018</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SAQLI score</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.44 (0 to 1.59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 0.42)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.50 (0 to 0.88)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0 (0 to 0.07)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.28 (0 to 1.59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.04 (0 to 0.42)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.066</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Data are median (range) values of area under the curve above baseline divided by time from randomisation to death. Data from <LINK REF="STD-Bourke-2006" TYPE="STUDY">Bourke 2006</LINK>.</P>
<P>Abbreviations: NIV: non-invasive ventilation; SAQLI: Sleep Apnea Quality of Life Index; SF-36 MCS: 36-Item Short-Form Health Survey Mental Component Summary; SF-36 PCS: 36-Item Short-Form Health Survey Physical Component Summary</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-06-15 18:59:15 +0100" MODIFIED_BY="Ruth  Brassington"/>
<FIGURES MODIFIED="2017-08-31 14:56:58 +0100" MODIFIED_BY="Ruth Brassington">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-08-31 14:49:58 +0100" MODIFIED_BY="Ruth Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>A flow diagram illustrating the study selection process.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5oAAAPSCAYAAAAa/qWKAACAAElEQVR42uydD0Rf3+P/PySTzMTk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-08-31 14:56:58 +0100" MODIFIED_BY="Ruth Brassington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. A green plus sign indicates low risk of bias
; a red minus sign indicates high risk of bias; and a yellow question mark indicates unclear risk of bias.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATgAAAGRCAIAAAB+DjgbAAARu0lEQVR42u3dvW5kRRPG8ZGQEIGD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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-08-31 14:50:59 +0100" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2015-12-10 21:56:36 +0000" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2015-12-10 21:56:36 +0000" MODIFIED_BY="Ruth Brassington">Cochrane Neuromuscular Specialised Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-12-09 11:06:35 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1 MeSH DESCRIPTOR Motor Neuron Disease Explode All [REFERENCE] [STANDARD]<BR/>#2 "moto? neuron? disease?" or "moto?neuron? disease?" [REFERENCE] [STANDARD]<BR/>#3 "charcot disease" [REFERENCE] [STANDARD]<BR/>#4 "amyotrophic lateral sclerosis" [REFERENCE] [STANDARD]<BR/>#5 als:ti or als:ab or nmd:ti or mnd:ab [REFERENCE] [STANDARD]<BR/>#6 #1 or #2 or #3 or #4 or #5 [REFERENCE] [STANDARD]<BR/>#7 MeSH DESCRIPTOR Respiration, Artificial [REFERENCE] [STANDARD]<BR/>#8 MeSH DESCRIPTOR Ventilators, Mechanical Explode All [REFERENCE] [STANDARD]<BR/>#9 MeSH DESCRIPTOR Respiratory Insufficiency Explode All [REFERENCE] [STANDARD]<BR/>#10 MeSH DESCRIPTOR Positive-Pressure Respiration Explode All [REFERENCE] [STANDARD]<BR/>#11 MeSH DESCRIPTOR Intubation, Intratracheal [REFERENCE] [STANDARD]<BR/>#12 (artificial NEXT respiration) or (mechanical NEXT ventilator*) [REFERENCE] [STANDARD]<BR/>#13 "respiratory insufficiency" or "positive pressure" or positivepressure or bipap or tracheotomy or tracheostomy or intubation [REFERENCE] [STANDARD]<BR/>#14 ("non invasive" or noninvasive) NEAR5 ventilation [REFERENCE] [STANDARD]<BR/>#15 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 [REFERENCE] [STANDARD]<BR/>#16 #6 AND #15 [REFERENCE] [STANDARD]<BR/>#17 (#6 AND #15) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-01-30 15:17:40 +0000" MODIFIED_BY="Angela A Gunn" NO="2">
<TITLE MODIFIED="2015-12-09 23:07:28 +0000" MODIFIED_BY="Angela A Gunn">CENTRAL (CRSO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-30 15:17:40 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1 MESH DESCRIPTOR Motor Neuron Disease EXPLODE ALL TREES<BR/>#2 ("motor neuron disease" OR "motor neurone disease" OR "motoneuron disease" OR "motorneuron disease" OR "amyotrophic lateral sclerosis"):TI,AB,KY<BR/>#3 (Gehrig* NEAR syndrome*):TI,AB,KY<BR/>#4 (Gehrig* NEAR disease*):TI,AB,KY<BR/>#5 #1 OR #2 OR #3 OR #4<BR/>#6 MESH DESCRIPTOR Ventilators, Mechanical EXPLODE ALL TREES<BR/>#7 MESH DESCRIPTOR Respiratory Insufficiency EXPLODE ALL TREES<BR/>#8 MESH DESCRIPTOR Intubation EXPLODE ALL TREES<BR/>#9 (artificial NEAR1 respiration):TI,AB,KY<BR/>#10 (mechanical NEAR1 ventilat*):TI,AB,KY<BR/>#11 (positive NEXT pressure next respiration):TI,AB,KY<BR/>#12 (tracheostomy or tracheotomy or intubation):TI,AB,KY<BR/>#13 (respiratory NEXT insufficiency):TI,AB,KY<BR/>#14 ((positive NEXT pressure) or positivepressure or bipap):TI,AB,KY<BR/>#15 (non NEXT invasive NEAR ventilation):TI,AB,KY<BR/>#16 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15<BR/>#17 #5 and #16</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-01-30 11:13:40 +0000" MODIFIED_BY="Angela A Gunn" NO="3">
<TITLE MODIFIED="2012-05-01 19:26:10 +0100" MODIFIED_BY="Angela A Gunn">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-30 11:13:40 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &lt;1946 to Present&gt;<BR/>MEDLINE(R) 1946 to December Week 1 2016<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (509791)<BR/>2 controlled clinical trial.pt. (98335)<BR/>3 randomized.ab. (440350)<BR/>4 placebo.ab. (205433)<BR/>5 drug therapy.fs. (2143873)<BR/>6 randomly.ab. (300053)<BR/>7 trial.ab. (473263)<BR/>8 groups.ab. (1841175)<BR/>9 or/1-8 (4401590)<BR/>10 exp animals/ not humans.sh. (4861434)<BR/>11 9 not 10 (3799680)<BR/>12 exp Motor Neuron Disease/ (26902)<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (8698)<BR/>14 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (211)<BR/>15 charcot disease.tw. (21)<BR/>16 Amyotrophic Lateral Sclerosis.mp. (25439)<BR/>17 or/12-16 (35394)<BR/>18 Respiration, Artificial/ (46571)<BR/>19 exp Ventilators, Mechanical/ (9120)<BR/>20 exp Respiratory Insufficiency/ (62240)<BR/>21 Positive-Pressure respiration/ (17376)<BR/>22 tracheotomy/ or tracheostomy/ (15141)<BR/>23 exp Intubation, Intratracheal/ (36501)<BR/>24 ((artificial adj1 respiration) or (mechanical adj1 ventilator$) or respiratory insufficiency or positive pressure$ or positivepressure$ or bipap or tracheotomy or tracheostomy or intubation).mp. (177327)<BR/>25 ((non invasive or noninvasive) adj5 ventilation).mp. (6294)<BR/>26 or/18-25 (204730)<BR/>27 11 and 17 and 26 (261)<BR/>28 remove duplicates from 27 (224)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-01-30 12:11:19 +0000" MODIFIED_BY="Angela A Gunn" NO="4">
<TITLE MODIFIED="2017-01-30 12:11:19 +0000" MODIFIED_BY="Angela A Gunn">Embase (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-30 11:48:17 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Embase &lt;1974 to 2017 January 26&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure.sh. (54965)<BR/>2 double-blind procedure.sh. (140535)<BR/>3 single-blind procedure.sh. (29251)<BR/>4 randomized controlled trial.sh. (476907)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1375392)<BR/>6 trial.ti. (222222)<BR/>7 or/1-6 (1537379)<BR/>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1771621)<BR/>9 animal/ or nonanimal/ or animal experiment/ (3818500)<BR/>10 9 not 8 (3101225)<BR/>11 7 not 10 (1421688)<BR/>12 Motor Neuron Disease/ or amyotrophic lateral sclerosis/ (37204)<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease$1).mp. (11931)<BR/>14 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (187)<BR/>15 charcot disease.tw. (26)<BR/>16 amyotrophic lateral sclerosis.tw. (23559)<BR/>17 or/12-16 (39624)<BR/>18 exp Artificial Ventilation/ (164181)<BR/>19 Ventilator/ (25931)<BR/>20 exp Respiratory Failure/ (85263)<BR/>21 exp Assisted Ventilation/ (141349)<BR/>22 Tracheotomy.mp. or TRACHEOTOMY/ (13209)<BR/>23 tracheostomy.mp. or TRACHEOSTOMY/ (23193)<BR/>24 RESPIRATORY TRACT INTUBATION/ (2942)<BR/>25 ((non invasive or noninvasive) adj5 ventilation).mp. (11674)<BR/>26 (artificial ventilat$ or artificial respiration or (mechanical adj1 ventilator$) or respiratory failure or respiratory insufficiency or positive pressure$ or positivepressure$ or bipap or assisted ventilation or intubation).mp. (263834)<BR/>27 or/18-26 (356006)<BR/>28 11 and 17 and 27 (206)<BR/>29 remove duplicates from 28 (194)<BR/>30 29 not medline.st. (190)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-08-04 07:30:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2017-08-04 07:30:37 +0100" MODIFIED_BY="[Empty name]">CINAHL Plus (EBSCOhost) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-30 12:10:56 +0000" MODIFIED_BY="Angela A Gunn">
<P>Monday, January 30, 2017 7:05:10 AM<BR/>
<BR/>S33 S31 AND S32 2<BR/>S32 EM 20151101- Limiters - Exclude MEDLINE records<BR/>Search modes - Boolean/Phrase 154,352<BR/>S31 S30 Limiters - Exclude MEDLINE records<BR/>Search modes - Boolean/Phrase 11<BR/>S30 S18 and S23 and S29 96<BR/>S29 S24 or S25 or S26 or S27 or S28 46,165<BR/>S28 (non invasive or noninvasive ) and ventilation 2,388<BR/>S27 (MH "Intubation, Intratracheal+") 11,461<BR/>S26 respiratory failure or Tracheotomy or Tracheostomy or intratracheal intubation 21,686<BR/>S25 mechanical ventilat* or positive pressure* or positivepressure* or bipap 19,602<BR/>S24 (MH "Mechanical Ventilation (Iowa NIC)") OR (MH "Ventilators, Mechanical") OR (MH "Respiration, Artificial") 16,209<BR/>S23 S19 or S20 or S21 or S22 7,215<BR/>S22 ("Amyotrophic Lateral Sclerosis") 3,195<BR/>S21 Lou Gehrig* and ( disease* or syndrome* ) 37<BR/>S20 (moto* neuron* disease* or moto?neuron* disease) 1,340<BR/>S19 (MH "Motor Neuron Diseases+") 6,504<BR/>S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 904,082<BR/>S17 ABAB design* 92<BR/>S16 TI random* or AB random* 196,479<BR/>S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial or sham? or dummy) ) 388,859<BR/>S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 147,267<BR/>S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 52,124<BR/>S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind* or mask*) ) 30,822<BR/>S11 PT ("clinical trial" or "systematic review") 132,091<BR/>S10 (MH "Factorial Design") 988<BR/>S9 (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") 297,562<BR/>S8 (MH "Meta Analysis") 26,160<BR/>S7 (MH "Solomon Four-Group Design") or (MH "Static Group Comparison") 53<BR/>S6 (MH "Quasi-Experimental Studies") 8,169<BR/>S5 (MH "Placebos") 9,984<BR/>S4 (MH "Double-Blind Studies") or (MH "Triple-Blind Studies") 34,806<BR/>S3 (MH "Clinical Trials+") 209,300<BR/>S2 (MH "Crossover Design") 14,288<BR/>S1 (MH "Random Assignment") or (MH "Random Sample") or (MH "Simple Random Sample") or (MH "Stratified Random Sample") or (MH "Systematic Random Sample") 74,845</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-01-30 15:15:22 +0000" MODIFIED_BY="Angela A Gunn" NO="6">
<TITLE MODIFIED="2013-02-15 14:52:50 +0000" MODIFIED_BY="Angela A Gunn">AMED (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-01-30 15:15:22 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: AMED (Allied and Complementary Medicine) &lt;1985 to January 2017&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 Randomized controlled trials/ (1815)<BR/>2 Random allocation/ (314)<BR/>3 Double blind method/ (608)<BR/>4 Single-Blind Method/ (80)<BR/>5 exp Clinical Trials/ (3589)<BR/>6 (clin$ adj25 trial$).tw. (6531)<BR/>7 ((singl$ or doubl$ or treb$ or trip$) adj25 (blind$ or mask$ or dummy)).tw. (2737)<BR/>8 placebos/ (578)<BR/>9 placebo$.tw. (2953)<BR/>10 random$.tw. (16335)<BR/>11 research design/ (1888)<BR/>12 Prospective Studies/ (941)<BR/>13 meta analysis/ (203)<BR/>14 (meta?analys$ or systematic review$).tw. (3023)<BR/>15 control$.tw. (33313)<BR/>16 (multicenter or multicentre).tw. (933)<BR/>17 ((study or studies or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).tw. (12019)<BR/>18 or/1-17 (51672)<BR/>19 Motor neuron disease/ (109)<BR/>20 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (182)<BR/>21 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (2)<BR/>22 charcot disease.tw. (1)<BR/>23 Amyotrophic Lateral Sclerosis/ (207)<BR/>24 amyotrophic lateral sclerosis.tw. (287)<BR/>25 or/19-24 (443)<BR/>26 exp Respiration artificial/ or artificial respiration.mp. (473)<BR/>27 Ventilators mechanical/ or mechanical ventilat$.mp. (441)<BR/>28 exp respiratory insufficiency/ (169)<BR/>29 respiratory insufficiency.mp. (151)<BR/>30 (positive pressure$ or positivepressure$).mp. (192)<BR/>31 bipap.mp. (4)<BR/>32 Tracheotomy/ or tracheotomy.mp. (31)<BR/>33 tracheostomy.mp. (84)<BR/>34 Intubation/ or intubation.mp. (123)<BR/>35 ((non invasive or noninvasive) adj5 ventilation).mp. (119)<BR/>36 or/26-35 (1112)<BR/>37 18 and 25 and 36 (6)<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2014-12-09 11:06:43 +0000" MODIFIED_BY="Angela A Gunn" NO="7">
<TITLE MODIFIED="2013-02-15 14:51:19 +0000" MODIFIED_BY="[Empty name]">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-09-20 18:41:09 +0100" MODIFIED_BY="[Empty name]">
<P>1 Ventilation in ALS</P>
<P>2 Non-invasive ventilation in ALS</P>
<P>3 Tracheostomy ventilation in ALS</P>
<P>4 Mechanical ventilation in ALS</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2017-08-31 14:50:18 +0100" MODIFIED_BY="Ruth Brassington" NO="8">
<TITLE MODIFIED="2017-08-31 14:50:18 +0100" MODIFIED_BY="Ruth Brassington">WHO International Clinical Trials Registry Platform search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-04-06 13:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>1 Ventilation in ALS</P>
<P>2 Non-invasive ventilation in ALS</P>
<P>3 Tracheostomy ventilation in ALS</P>
<P>4 Mechanical ventilation in ALS</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2017-08-31 14:50:59 +0100" MODIFIED_BY="Ruth Brassington" NO="9">
<TITLE MODIFIED="2016-05-17 17:46:22 +0100" MODIFIED_BY="Ruth  Brassington">Additional methods</TITLE>
<APPENDIX_BODY MODIFIED="2017-08-31 14:50:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>If meta-analysis becomes possible with the inclusion of more trials, we will use the following methods, which are based on a standard template developed by Cochrane Airways and modified by the Cochrane Neuromuscular Disease Group.</P>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect</HEADING>
<P>For the primary outcome measure we planned to calculate an overall measure of treatment efficacy combining survival results at different time points. This measure is based on estimating a pooled hazard ratio (i.e. at any given time point the risk of death for the survivors in the treated group divided by risk of death for the survivors in the control group) as described by <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>. We wanted to use this measure rather than the summary risk ratio (RR) calculated by the Cochrane statistical software, Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), because the Parmar method uses all the data on survival from the whole observation period, whereas Review Manager 5 needs the survival rates at the same fixed point in time since the start of observation to be reported for all the studies if they are to be combined.</P>
<P>For the secondary outcome measures reported as continuous variables, we planned to calculate a mean of the difference between their effects using Review Manager 5. Had we found trials using dichotomous outcome measures such as death rates after a fixed time, for example three months, we planned to obtain RR with 95% confidence interval (CI).</P>
<P>Had we found trials where the studies measured continuous outcomes that are conceptually the same but are measured in different ways (such as different assessment scales), we planned to combine the results and express them as standardised mean differences (using standard deviation units) with 95% CI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity</HEADING>
<P>We planned to use the I² statistic for quantifying inconsistency across trials in any meta-analysis, as described in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, using the following as a rough guide for interpretation (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<UL>
<LI>0% to 40%: low heterogeneity;</LI>
<LI>30% to 60%: may represent moderate heterogeneity;</LI>
<LI>50% to 90%: may represent substantial heterogeneity;</LI>
<LI>75% to 100%: considerable heterogeneity.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases</HEADING>
<P>If in the future we identify more trials, we will assess small-study effects using funnel plots; however, these must be interpreted with caution and are not considered useful if fewer than 10 trials are included in an analysis (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>We planned to use Review Manager 5 for data synthesis if possible. We planned to use a fixed-effect analysis, and to use a random-effects analysis in the event of unexplained heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity</HEADING>
<P>Had we found heterogeneity of a moderate or greater level, we planned to first check the data and then consider whether pooling the data was justified. We would then have undertaken a sensitivity analysis by repeating the calculation omitting the trials at high risk of bias. If heterogeneity was not explained by variations in trial quality, we would have used a random-effects approach to obtain the pooled estimates from the group of trials.</P>
<P>Subgroups of interest were participants with or without significant bulbar symptoms as categorised by the authors of the papers reviewed.</P>
<P>We considered non-randomised evidence concerning adverse events and the cost and cost-effectiveness of different forms of mechanical ventilation in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We planned to undertake sensitivity analyses to demonstrate the effect of downweighting or ignoring those studies that were at high risk of bias on individual criteria, if sufficient numbers of trials and relevant data were available for meta-analysis.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 included studies in existing review&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 full-text article assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;217&lt;/span&gt; records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;New records identified through database searching for the update:&lt;/p&gt;&lt;p&gt;MEDLINE - 78&lt;/p&gt;&lt;p&gt;Embase - 92&lt;/p&gt;&lt;p&gt;AMED - &lt;span&gt;0&lt;/span&gt;&lt;/p&gt;&lt;p&gt;CINAHL Plus - 2&lt;/p&gt;&lt;p&gt;Cochrane Neuromuscular Specialised Register - 33&lt;/p&gt;&lt;p&gt;CENTRAL - 37&lt;/p&gt;&lt;p&gt;Total &lt;span&gt;242&lt;/span&gt; new references&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No studies identified from clinical trials registries for inclusion in the review&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;77 records in clinical trials registries after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;77 records identified by searching ClinicalTrials.gov&lt;/p&gt;&lt;p&gt;&lt;span&gt;2 &lt;/span&gt;records identified by searching WHO ICTRP&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;2 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;77 studies excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;216 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 full-text article excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>